Affiliations
Division of General Medicine and Primary Care, (Herzig, Cheung, Ngo, Marcantonio), Beth Israel Deaconess Medical Center
Harvard Medical School (Herzig, Ngo, Marcantonio)
Division of Gerontology (Marcantonio), Beth Israel Deaconess Medical Center, Boston, Massachusetts
Given name(s)
Long H.
Family name
Ngo
Degrees
PhD

Two‐Item Bedside Test for Delirium

Article Type
Changed
Tue, 05/16/2017 - 22:59
Display Headline
Preliminary development of an ultrabrief two‐item bedside test for delirium

Delirium (acute confusion) is common in older adults and leads to poor outcomes, such as death, clinician and caregiver burden, and prolonged cognitive and functional decline.[1, 2, 3, 4] Delirium is extremely costly, with estimates ranging from $143 to $152 billion annually (2005 US$).[5, 6] Early detection and management may improve the poor outcomes and reduce costs attributable to delirium,[3, 7] yet delirium identification in clinical practice has been challenging, particularly when translating research tools to the bedside.[8, 9, 10]As a result, only 12% to 35% of delirium cases are detected in routine care, with hypoactive delirium and delirium superimposed on dementia most likely to be missed.[11, 12, 13, 14, 15]

To address these issues, we recently developed and published the three‐dimensional Confusion Assessment Method (3D‐CAM), the 3‐minute diagnostic assessment for CAM‐defined delirium.[16] The 3D‐CAM is a structured assessment tool that includes mental status testing, patient symptom probes, and guided interviewer observations for signs of delirium. 3D‐CAM items were selected through a rigorous process to determine the most informative items for the 4 CAM diagnostic features.[17] The 3D‐CAM can be completed in 3 minutes, and has 95% sensitivity and 94% specificity relative to a reference standard.[16]

Despite the capabilities of the 3D‐CAM, there are situations when even 3 minutes is too long to devote to delirium identification. Moreover, a 2‐step approach in which a sensitive ultrabrief screen is administered, followed by the 3D‐CAM in positives, may be the most efficient approach for large‐scale delirium case identification. The aim of the current study was to use the 3D‐CAM database to identify the most sensitive single item and pair of items in the diagnosis of delirium, using the reference standard in the diagnostic accuracy analysis. We hypothesized that we could identify a single item with greater than 80% sensitivity and a pair of items with greater than 90% sensitivity for detection of delirium.

METHODS

Study Sample and Design

We analyzed data from the 3D‐CAM validation study,[16] which prospectively enrolled participants from a large urban teaching hospital in Boston, Massachusetts, using a consecutive enrollment sampling strategy. Inclusion criteria were: (1) 75 years old, (2) admitted to general or geriatric medicine services, (3) able to communicate in English, (4) without terminal conditions, (5) expected hospital stay of 2 days, (6) not a previous study participant. Experienced clinicians screened patients for eligibility. If the patient lacked capacity to provide consent, the designated surrogate decision maker was contacted. The study was approved by the institutional review board.

Reference Standard Delirium Diagnosis

The reference standard delirium diagnosis was based on an extensive (45 minutes) face‐to‐face patient interview by experienced clinician assessors (neuropsychologists or advanced practice nurses), medical record review, and input from the nurse and family members. This comprehensive assessment included: (1) reason for hospital admission, hospital course, and presence of cognitive concerns, (2) family, social, and functional history, (3) Montreal Cognitive Assessment,[18] (4) Geriatric Depression Scale,[19] (5) medical record review including scoring of comorbidities using the Charlson index,[20] determination of functional status using the basic and Instrumental Activities of Daily Living,[21, 22] psychoactive medications administered, and (6) a family member interview to assess the patient's baseline cognitive status that included the Eight‐Item Interview to Differentiate Aging and Dementia,[23] to assess the presence of dementia. Using all of these data, an expert panel, including the clinical assessor, the study principal investigator (E.R.M.), a geriatrician, and an experienced neuropsychologist, adjudicated the final delirium diagnoses using Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM‐IV) criteria. The panel also adjudicated for the presence or absence of dementia and mild cognitive impairment based on National Institute on Aging‐Alzheimer's Association (NIA‐AA) criteria.[24] This approach has been used in other delirium studies.[25]

3D‐CAM Assessments

After the reference standard assessment, the 3D‐CAM was administered by trained research assistants (RAs) who were blinded to the results of the reference standard. To reduce the likelihood of fluctuations or temporal changes, all assessments were completed between 11:00 am and 2:00 pm and for each participant, within a 2‐hour time period (for example, 11:23 am to 1:23 pm).

Statistical Analyses to Determine the Best Single‐ and Two‐Item Screeners

To determine the best single 3D‐CAM item to identify delirium, the responses of the 20 individual items in the 3D‐CAM (see Supporting Table 1 in the online version of this article) were compared to the reference standard to determine their sensitivity and specificity. Similarly, an algorithm was used to generate all unique 2‐item combinations of the 20 items (190 unique pairs), which were compared to the reference. An error, no response, or an answer of I do not know by the patient was considered a positive screen for delirium. The 2‐item screeners were considered positive if 1 or both of the items were positive. Sensitivity and specificity were calculated along with 95% confidence intervals (CIs).

Subset analyses were performed to determine sensitivity and specificity of individual items and pairs of items stratified by the patient's baseline cognitive status. Two strata were createdpatients with dementia (N=56), and patients with normal baseline cognitive status or mild cognitive impairment (MCI) (N=145). We chose to group MCI with normal for 2 reasons: (1) dementia is a well‐established and strong risk factor for delirium, whereas the evidence for MCI being a risk factor for delirium is less established and (2) to achieve adequate allocation of delirious cases in both strata. Last, we report the sensitivity of altered level of consciousness (LOC), which included lethargy, stupor, coma, and hypervigilance as a single screening item for delirium in the overall sample and by cognitive status. Analyses were conducted using commercially available software (SAS version 9.3; SAS Institute, Inc., Cary, NC).

RESULTS

Characteristics of the patients are shown in Table 1. Subjects had a mean age of 84 years, 62% were female, and 28% had a baseline dementia. Forty‐two (21%) had delirium based on the clinical reference standard. Twenty (10%) had less than a high school education and 100 (49%) had at least a college education.

Sample Characteristics (N=201)
CharacteristicN (%)
  • NOTE: Abbreviations: ADL, activities of daily living; IADL, instrumental activities of daily living; MCI, mild cognitive impairment; MoCA, Montreal Cognitive Assessment; SD, standard deviation.

Age, y, mean (SD)84 (5.4)
Sex, n (%) female125 (62)
White, n (%)177 (88)
Education, n (%) 
Less than high school20 (10)
High school graduate75 (38)
College plus100 (49)
Vision interfered with interview, n (%)5 (2)
Hearing interfered with interview, n (%)18 (9)
English second language n (%)10 (5)
Charlson, mean (SD)3 (2.3)
ADL, n (% impaired)110 (55)
IADL, n (% impaired)163 (81)
MCI, n (%)50 (25)
Dementia, n (%)56 (28)
Delirium, n (%)42 (21)
MoCA, mean (SD)19 (6.6)
MoCA, median (range)20 (030)

Single Item Screens

Table 2 reports the results of single‐item screens for delirium with sensitivity, the ability to correctly identify delirium when it is present by the reference standard, and specificity, the ability to correctly identify patients without delirium when it is not present by reference standard and 95% CIs. Items are listed in descending order of sensitivity; in the case of ties, the item with the higher specificity is listed first. The screening items with the highest sensitivity for delirium are Months of the year backwards, and Four digits backwards, both with a sensitivity of 83% (95% CI: 69%‐93%). Of these 2 items, Months of the year backwards had a much better specificity of 69% (95% CI: 61%‐76%), whereas Four digits backwards had a specificity of 52% (95% CI: 44%‐60%). The item What is the day of the week? had lower sensitivity at 71% (95% CI: 55%‐84%), but excellent specificity at 92% (95% CI: 87%‐96%).

Top Ten Single‐Item Screen for Delirium (N=201)
Screen ItemScreen Positive (%)cSensitivity (95% CI)Specificity (95% CI)LRLR
  • NOTE: Number of patients with delirium=42. Abbreviations: CI, confidence interval; LR, likelihood ratio.

  • There were 20 different items and 190 possible item pairs considered.

  • Top 10 items: our primary criterion for determining this was sensitivity, with a secondary criterion of specificity in the case of ties. Items are listed in descending order on this basis.

  • Screen positive: error, do not know, or no response.

Months of the year backwards420.83 (0.69‐0.93)0.69 (0.61‐0.76)2.70.24
Four digits backwards560.83 (0.69‐0.93)0.52 (0.44‐0.60)1.720.32
What is the day of the week?210.71 (0.55‐0.84)0.92 (0.87‐0.96)9.460.31
What is the year?160.55 (0.39‐0.70)0.94 (0.9‐0.97)9.670.48
Have you felt confused during the past day?140.50 (0.34‐0.66)0.95 (0.9‐0.98)9.940.53
Days of the week backwards150.50 (0.34‐0.66)0.94 (0.89‐0.97)7.950.53
During the past day, did you see things that were not really there?110.45 (0.3‐0.61)0.97 (0.94‐0.99)17.980.56
Three digits backwards150.45 (0.3‐0.61)0.92 (0.87‐0.96)5.990.59
What type of place is this?90.38 (0.24‐0.54)0.99 (0.96‐1)30.290.63
During the past day, did you think you were not in the hospital?100.38 (0.24‐0.54)0.97 (0.94‐0.99)15.140.64

We then examined performance of single‐item screeners in patients with and without dementia (Table 3). In persons with dementia, the best single item was also Months of the year backwards, with a sensitivity of 89% (95% CI: 72%‐98%) and a specificity of 61% (95% CI: 41%‐78%). In persons with normal baseline cognition or MCI, the best performing single item was Four digits backwards, with sensitivity of 79% (95% CI: 49%‐95%) and specificity of 51% (95% CI: 42%‐60%). Months of the year backwards also performed well, with sensitivity of 71% (95% CI: 42%‐92%) and specificity of 71% (95% CI: 62%‐79%).

Top Three Single‐Item Screen for Delirium Stratified by Baseline Cognition
Test ItemNormal/MCI Patients (n=145)Dementia Patients (n=56)
Screen Positive (%)bSensitivity (95% CI)Specificity (95% CI)LRLRScreen Positive (%)bSensitivity (95% CI)Specificity (95% CI)LRLR
  • NOTE: Participants with learning problems (1) grouped with dementia and MCI participants (44) grouped with normal. Number of patients with delirium=28. Abbreviations: CI, confidence interval; LR, likelihood ratio; MCI, mild cognitive impairment.

  • Top 3 items: our primary criterion for determining this was sensitivity, with a secondary criterion of specificity in the case of ties. Items are listed in descending order on this basis.

  • Screen positive: error, do not know, or no response.

Months backwards330.71 (0.42‐0.92)0.71 (0.62‐0.79)2.460.4640.89 (0.72‐0.98)0.61 (0.41‐0.78)2.270.18
Four digits backwards520.79 (0.49‐0.95)0.51 (0.42‐0.60)1.610.42660.86 (0.67‐0.96)0.54 (0.34‐0.72)1.850.27
What is the day of the week?100.64 (0.35‐0.87)0.96 (0.91‐0.99)16.840.37500.75 (0.55‐0.89)0.75 (0.55‐0.89)30.33

Two‐Item Screens

Table 4 reports the results of 2‐item screens for delirium with sensitivity, specificity, and 95% CIs. Item pairs are listed in descending order of sensitivity following the same convention as in Table 2. The 2‐item screen with the highest sensitivity for delirium is the combination of What is the day of the week? and Months of the year backwards, with a sensitivity of 93% (95% CI: 81%‐99%) and specificity of 64% (95% CI: 56%‐70%). This screen had a positive and negative likelihood ratio (LR) of 2.59 and 0.11, respectively. The combination of What is the day of the week? and Four digits backwards had the same sensitivity 93% (95% CI: 81%‐99%), but lower specificity of 48% (95% CI: 40%‐56%). The combination of What type of place is this? (hospital) and Four digits backwards had a sensitivity of 90% (95% CI: 77%‐97%) and specificity of 51% (95% CI: 43%‐50%).

Top Ten Two‐Item Screen for Delirium (N=201)
Screen Item 1Screen Item 2Screen Positive (%)cSensitivity (95% CI)Specificity (95% CI)LRLR
  • NOTE: Number of patients with delirium=42. Abbreviations: CI, confidence interval; LR, likelihood ratio.

  • There were 20 different items and 190 possible item pairs considered.

  • Top 10 items: our primary criterion for determining this was sensitivity, with a secondary criterion of specificity in the case of ties. Items are listed in descending order on this basis.

  • Screen positive: error, do not know, or no response.

What is the day of the week?Months backwards480.93 (0.81‐0.99)0.64 (0.56‐0.70)2.590.11
What is the day of the week?Four digits backwards600.93 (0.81‐0.99)0.48 (0.4‐0.56)1.80.15
Four digits backwardsMonths backwards650.93 (0.81‐0.99)0.42 (0.34‐0.50)1.60.17
What type of place is this?Four digits backwards580.90 (0.77‐0.97)0.51 (0.43‐0.50)1.840.19
What is the year?Four digits backwards590.9 (0.77‐0.97)0.5 (0.42‐0.5)1.800.19
What is the day of the week?Three digits backwards300.88 (0.74‐0.96)0.86 (0.79‐0.90)6.090.14
What is the year?Months backwards440.88 (0.74‐0.96)0.68 (0.6‐0.75)2.750.18
What type of place is this?Months backwards430.86 (0.71‐0.95)0.69 (0.61‐0.70)2.730.21
During the past day, did you think you were not in the hospital?Months backwards430.86 (0.71‐0.95)0.69 (0.61‐0.70)2.730.21
Days of the week backwardsMonths backwards430.86 (0.71‐0.95)0.68 (0.6‐0.75)2.670.21

When subjects were stratified by baseline cognition, the best 2‐item screens for normal and MCI patients was What is the day of the week? and Four digits backwards, with 93% sensitivity (95% CI: 66%‐100%) and 50% specificity (95% CI: 42%‐59%). The best pair of items for patients with dementia (Table 5) was the same as the overall sample, What is the day of the week? and Months of the year backwards, but its performance differed with a higher sensitivity of 96% (95% CI: 82%‐100%) and lower specificity of 43% (95% CI: 24%‐63%). This same pair of items had 86% sensitivity (95% CI: 57%‐98%) and 69% (95% CI: 60%‐77%) specificity for persons with either normal cognition or MCI.

Top Three Two‐Item Screen for Normal/MCI and Persons With Dementia
Test Item 1Test Item 2Normal/MCI Patients (n=145)Dementia Patients (n=56) 
Item Positive (%)bSensitivity (95% CI)Specificity (95% CI)LRLRItem Positive (%)bSensitivity (95% CI)Specificity (95% CI)LRLR
  • NOTE: Participants with learning problems (1) grouped with dementia and MCI participants (44) grouped with normal. Number of patients with delirium=28. Abbreviations: CI, confidence interval; LR, likelihood ratio; MCI, mild cognitive impairment.

  • Top 3 items: our primary criterion for determining this was sensitivity, with a secondary criterion of specificity in the case of ties. Items are listed in descending order on this basis.

  • Screen positive: error, do not know, or no response.

What is the day of the week?Months backwards360.86 (0.57‐0.98)0.69 (0.60‐0.77)2.740.21770.96 (0.82‐1)0.43 (0.24‐0.63)1.690.08
What is the day of the week?Four digits backwards540.93 (0.66‐1)0.5 (0.42‐0.59)1.870.14770.93 (0.76‐0.99)0.39 (0.22‐0.59)1.530.18
Four digits backwardsMonths backwards610.93 (0.66‐1)0.43 (0.34‐0.52)1.620.17770.93 (0.76‐0.99)0.39 (0.22‐0.59)1.530.18

Altered Level of Consciousness as a Screener for Delirium

Altered level of consciousness (ALOC) was uncommon in our sample, with an overall prevalence of 10/201 (4.9%). When examined as a screening item for delirium, ALOC had very poor sensitivity of 19% (95% CI: 9%‐34%) but had excellent specificity 99% (95% CI: 96%‐100%). Altered LOC also demonstrated poor screening performance when stratified by cognitive status, with a sensitivity of 14% in the normal and MCI group (95% CI: 2%‐43%) and sensitivity of 21% (95% CI: 8%‐41%) in persons with dementia.

Positive and Negative Predictive Values

Although we focused on sensitivity and specificity in evaluating 1‐ and 2‐item screeners, we also examined positive and negative predictive values. These values will vary depending on the overall prevalence of delirium, which was 21% in this dataset. The best 1‐item screener, Months of the year backwards, had a positive predictive value of 31% and negative predictive value of 94%. The best 2‐item screener, Months of the year backwards with What is the day of the week?, had a positive predictive value of 41% and negative predictive value of 97% (see Supporting Tables 2 and 3 in the online version of this article) LRs for the items are in Tables 2 through 5.

DISCUSSION

Identifying simple, efficient, bedside case‐identification methods for delirium is an essential step toward improving recognition of this highly morbid syndrome in hospitalized older adults. In this study, we identified a single cognitive item, Months of the year backwards, that identified 83% of delirium cases when compared with a reference standard diagnosis. Furthermore, we identified 2 items, Months of the year backwards and What is the day of the week? which when used in combination identified 93% of delirium cases. The same 1 and 2 items also worked well in patients with dementia, in whom delirium is often missed. Although these items require further clinical validation, the development of an ultrabrief 2‐item test that identifies over 90% of delirium cases and can be completed in less than 1 minute (recently, we administered the best 2‐item screener to 20 consecutive general medicine patients over age 70 years, and it was completed in a median of 36.5 seconds), holds great potential for simplifying bedside delirium screening and improving the care of hospitalized older adults.

Our current findings both confirm and extend the emerging literature on best screening items for delirium. Sands and colleagues (2010)[26] tested a single test for delirium, Do you think (name of patient) has been more confused lately? in 21 subjects and achieved a sensitivity of 80%. Han and colleagues developed a screening tool in emergency‐department patients using the LOC question from the Richmond Agitation‐Sedation Scale and spelling the word lunch backwards, and achieved 98% sensitivity, but in a younger emergency department population with a low prevalence of dementia.[27] O'Regan et al. recently also found Months of the year backwards to be the best single‐screening item for delirium in a large sample, but only tested a 1‐item screen.[28] Our study extends these studies in several important ways by: (1) employing a rigorous clinical reference standard diagnosis of delirium, (2) having a large sample with a high prevalence of patients with dementia, (3) use of a general medical population, and (4) examining the best 2‐item screens in addition to the best single item.

Systematic intervention programs[29, 30, 31] that focus on improved delirium evaluation and management have the potential to improve patient outcomes and reduce costs. However, targeting these programs to patients with delirium has proven difficult, as only 12% to 35% of delirium cases are recognized in routine clinical practice.[11, 12, 13, 14, 15] The 1‐ and 2‐item screeners we identified could play an important role in future delirium identification. The 3D‐CAM combines high sensitivity (95%) with high specificity (94%)[16] and therefore would be an excellent choice as the second step after a positive screen. The feasibility, effectiveness, and cost of administering these screeners, followed by a brief diagnostic tool such as the 3D‐CAM, should be evaluated in future work.

Our study has noteworthy strengths, including the use of a large purposefully challenging clinical sample with advanced age that included a substantial proportion with dementia, a detailed assessment, and the testing of very brief and practical tools for bedside delirium screening.[25] This study also has several important limitations. Most importantly, we presented secondary analysis of individual items and pairs of items drawn from the 3D CAM assessment; therefore, the 2‐item bedside screen requires prospective clinical validation. The reference standard was based on the DSM‐IV, because this study was conducted prior to the release of DSM‐V. In addition, the ordering of the reference standard and 3D‐CAM assessments was not randomized due to feasibility constraints. In addition, this study was cross‐sectional, involved only a single hospital, and enrolled only older medical patients during the day shift. Our sample was older (aged 75 years and older), and a younger sample may have had a different prevalence of delirium, which could affect the positive predictive value of our ultrabrief screen. We plan to test this in a sample of patients aged 70 years and older in future studies. Finally, it should be noted that these best 1‐item and 2‐item screeners miss 17% and 7% of delirium cases, respectively. In cases where this is unacceptably high, alternative approaches might be necessary.

It is important to remember that these 1‐ and 2‐item screeners are not diagnostic tools and therefore should not be used in isolation. Optimally, they will be followed by a more specific evaluation, such as the 3D‐CAM, as part of a systematic delirium identification process. For instance, in our sample (with a delirium rate of 21%), the best 2‐item screener had a positive predictive value of 41%, meaning that positive screens are more likely to be false positives than true positives (see Supporting Tables 2 and 3 in the online version of this article).[32] Nevertheless, by reducing the total number of patients who require diagnostic instrument administration, use of these ultrabrief screeners can improve efficiency and result in a net benefit to delirium case‐identification efforts.[32]

Time has been demonstrated to be a barrier to delirium identification in previous studies, but there are likely others. These may include, for instance, staff nihilism about screening making a difference, ambiguous responsibility for delirium screening and management, unsupportive system leadership, and absent payment for these activities.[31] Moreover, it is possible that the 2‐step process we propose may create an incentive for staff to avoid positive screens as they see it creating more work for themselves. We plan to identify and address such barriers in our future work.

In conclusion, we identified a single screening item for delirium, Months of the year backwards, with 83% sensitivity, and a pair of items, Months of the year backwards and What is the day of the week?, with 93% sensitivity relative to a rigorous reference standard diagnosis. These ultrabrief screening items work well in patients with and without dementia, and should require very little training of staff. Future studies should further validate these tools, and determine their translatability and scalability into programs for systematic, widespread delirium detection. Developing efficient and accurate case identification strategies is a necessary prerequisite to appropriately target delirium management protocols, enabling healthcare systems to effectively address this costly and deadly condition.

Disclosures

Author contributionsD.M.F. conceived the study idea, participated in its design and coordination, and drafted the initial manuscript. S.K.I. contributed to the study design and conceptualization, supervision, funding, preliminary analysis, and interpretation of the data, and critical revision of the manuscript. J.G. conducted the analysis for the study and critically revised the manuscript. L.N. supervised the analysis for the study and critically revised the manuscript. R.J. contributed to the study design and critical revision of the manuscript. J.S.S. critically revised the manuscript. E.R.M. obtained funding for the study, supervised all data collection, assisted in drafting and critically revising the manuscript, and contributed to the conceptualization, design, and supervision of the study. All authors have seen and agree with the contents of the manuscript.

This work was supported by the National Institute of Aging grant number R01AG030618 and K24AG035075 to Dr. Marcantonio. Dr. Inouye's time was supported in part by grants P01AG031720, R01AG044518, and K07AG041835 from the National Institute on Aging. Dr. Inouye holds the Milton and Shirley F. Levy Family Chair (Hebrew Senior Life/Harvard Medical School). Dr. Fick is partially supported from National Institute of Nursing Research grant number R01 NR011042. Dr. Saczynski was supported in part by funding from the National Institute on Aging (K01AG33643) and from the National Heart Lung and Blood Institute (U01HL105268). The funding agencies had no role and the authors retained full autonomy in the preparation of this article. All authors and coauthors have no financial or nonfinancial conflicts of interest to disclose regarding this article.

This article was presented at the Presidential Poster Session at the American Geriatrics Society 2014 Annual Meeting in Orlando, Florida, May 14, 2014.

Files
References
  1. Witlox J, Eurelings LS, Jonghe JF, Kalisvaart KJ, Eikelenboom P, Gool WA. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta‐analysis. JAMA. 2010;304(4):443451.
  2. Saczynski JS, Marcantonio ER, Quach L, et al. Cognitive trajectories after postoperative delirium. N Engl J Med. 2012;367(1):3039.
  3. Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet. 2014;383:911922.
  4. Fick DM, Steis MR, Waller JL, Inouye SK. Delirium superimposed on dementia is associated with prolonged length of stay and poor outcomes in hospitalized older adults. J Hosp Med. 2013;8(9):500505.
  5. Leslie DL, Marcantonio ER, Zhang Y, Leo‐Summers L, Inouye SK. One‐year health care costs associated with delirium in the elderly population. Arch Intern Med. 2008;168(1):2732.
  6. Leslie DL, Inouye SK. The importance of delirium: Economic and societal costs. J Am Geriatr Soc. 2011;59(suppl 2):S241S243.
  7. Marcantonio ER. Delirium. Ann Intern Med. 2011;154(11):ITC6.
  8. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50.
  9. Rice KL, Bennett MJ, Clesi T, Linville L. Mixed‐methods approach to understanding nurses' clinical reasoning in recognizing delirium in hospitalized older adults. J Contin Educ Nurs. 2014;45:1–13.
  10. Yanamadala M, Wieland D, Heflin MT. Educational interventions to improve recognition of delirium: a systematic review. J Am Geriatr Soc. 2013;61(11):19831993.
  11. Steis MR, Fick DM. Delirium superimposed on dementia: accuracy of nurse documentation. J Gerontol Nurs. 2012;38(1):3242.
  12. Lemiengre J, Nelis T, Joosten E, et al. Detection of delirium by bedside nurses using the confusion assessment method. J Am Geriatr Soc. 2006;54:685689.
  13. Milisen K, Foreman MD, Wouters B, et al. Documentation of delirium in elderly patients with hip fracture. J Gerontol Nurs. 2002;28(11):2329.
  14. Kales HC, Kamholz BA, Visnic SG, Blow FC. Recorded delirium in a national sample of elderly inpatients: potential implications for recognition. J Geriatr Psychiatry Neurol. 2003;16(1):3238.
  15. Saczynski JS, Kosar CM, Xu G, et al. A tale of two methods: chart and interview methods for identifying delirium. J Am Geriatr Soc. 2014;62(3):518524.
  16. Marcantonio E, Ngo L, Jones R, et al. 3D‐CAM: Derivation and validation of a 3‐minute diagnostic interview for CAM‐defined delirium: a cross‐sectional diagnostic test study. Ann Intern Med. 2014;161(8):554561.
  17. Yang FM, Jones RN, Inouye SK, et al. Selecting optimal screening items for delirium: an application of item response theory. BMC Med Res Methodol. 2013;13:8.
  18. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695699.
  19. Yesavage JA. Geriatric Depression Scale. Psychopharmacol Bull. 1988;24(4):709711.
  20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373383.
  21. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914919.
  22. Lawton MP, Brody EM. Assessment of older people: self‐maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179186.
  23. Galvin J, Roe C, Powlishta K, et al. The AD8: a brief informant interview to detect dementia. Neurology. 2005;65(4):559564.
  24. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263269.
  25. Neufeld KJ, Nelliot A, Inouye SK, et al. Delirium diagnosis methodology used in research: a survey‐based study. Am J Geriatr Psychiatry. 2014;22(12):15131521.
  26. Sands M, Dantoc B, Hartshorn A, Ryan C, Lujic S. Single Question in Delirium (SQiD): testing its efficacy against psychiatrist interview, the Confusion Assessment Method and the Memorial Delirium Assessment Scale. Palliat Med. 2010;24(6):561565.
  27. Han JH, Wilson A, Vasilevskis EE, et al. Diagnosing delirium in older emergency department patients: validity and reliability of the delirium triage screen and the brief confusion assessment method. Ann Emerg Med. 2013;62(5):457465.
  28. O'Regan NA, Ryan DJ, Boland E, et al. Attention! A good bedside test for delirium? J Neurol Neurosurg Psychiatry. 2014;85(10):11221131.
  29. Bergmann MA, Murphy KM, Kiely DK, Jones RN, Marcantonio ER. A model for management of delirious postacute care patients. J Am Geriatr Soc. 2005;53(10):18171825.
  30. Fick DM, Steis MR, Mion LC, Walls JL. Computerized decision support for delirium superimposed on dementia in older adults: a pilot study. J Gerontol Nurs. 2011;37(4):3947.
  31. Yevchak AM, Fick DM, McDowell J, et al. Barriers and facilitators to implementing delirium rounds in a clinical trial across three diverse hospital settings. Clin Nurs Res. 2014;23(2):201215.
  32. Meehl PE, Rosen A. Antecedent probability and the efficiency of psychometric signs, patterns, or cutting scores. Psychol Bull. 1955;52(3):194.
Article PDF
Issue
Journal of Hospital Medicine - 10(10)
Publications
Page Number
645-650
Sections
Files
Files
Article PDF
Article PDF

Delirium (acute confusion) is common in older adults and leads to poor outcomes, such as death, clinician and caregiver burden, and prolonged cognitive and functional decline.[1, 2, 3, 4] Delirium is extremely costly, with estimates ranging from $143 to $152 billion annually (2005 US$).[5, 6] Early detection and management may improve the poor outcomes and reduce costs attributable to delirium,[3, 7] yet delirium identification in clinical practice has been challenging, particularly when translating research tools to the bedside.[8, 9, 10]As a result, only 12% to 35% of delirium cases are detected in routine care, with hypoactive delirium and delirium superimposed on dementia most likely to be missed.[11, 12, 13, 14, 15]

To address these issues, we recently developed and published the three‐dimensional Confusion Assessment Method (3D‐CAM), the 3‐minute diagnostic assessment for CAM‐defined delirium.[16] The 3D‐CAM is a structured assessment tool that includes mental status testing, patient symptom probes, and guided interviewer observations for signs of delirium. 3D‐CAM items were selected through a rigorous process to determine the most informative items for the 4 CAM diagnostic features.[17] The 3D‐CAM can be completed in 3 minutes, and has 95% sensitivity and 94% specificity relative to a reference standard.[16]

Despite the capabilities of the 3D‐CAM, there are situations when even 3 minutes is too long to devote to delirium identification. Moreover, a 2‐step approach in which a sensitive ultrabrief screen is administered, followed by the 3D‐CAM in positives, may be the most efficient approach for large‐scale delirium case identification. The aim of the current study was to use the 3D‐CAM database to identify the most sensitive single item and pair of items in the diagnosis of delirium, using the reference standard in the diagnostic accuracy analysis. We hypothesized that we could identify a single item with greater than 80% sensitivity and a pair of items with greater than 90% sensitivity for detection of delirium.

METHODS

Study Sample and Design

We analyzed data from the 3D‐CAM validation study,[16] which prospectively enrolled participants from a large urban teaching hospital in Boston, Massachusetts, using a consecutive enrollment sampling strategy. Inclusion criteria were: (1) 75 years old, (2) admitted to general or geriatric medicine services, (3) able to communicate in English, (4) without terminal conditions, (5) expected hospital stay of 2 days, (6) not a previous study participant. Experienced clinicians screened patients for eligibility. If the patient lacked capacity to provide consent, the designated surrogate decision maker was contacted. The study was approved by the institutional review board.

Reference Standard Delirium Diagnosis

The reference standard delirium diagnosis was based on an extensive (45 minutes) face‐to‐face patient interview by experienced clinician assessors (neuropsychologists or advanced practice nurses), medical record review, and input from the nurse and family members. This comprehensive assessment included: (1) reason for hospital admission, hospital course, and presence of cognitive concerns, (2) family, social, and functional history, (3) Montreal Cognitive Assessment,[18] (4) Geriatric Depression Scale,[19] (5) medical record review including scoring of comorbidities using the Charlson index,[20] determination of functional status using the basic and Instrumental Activities of Daily Living,[21, 22] psychoactive medications administered, and (6) a family member interview to assess the patient's baseline cognitive status that included the Eight‐Item Interview to Differentiate Aging and Dementia,[23] to assess the presence of dementia. Using all of these data, an expert panel, including the clinical assessor, the study principal investigator (E.R.M.), a geriatrician, and an experienced neuropsychologist, adjudicated the final delirium diagnoses using Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM‐IV) criteria. The panel also adjudicated for the presence or absence of dementia and mild cognitive impairment based on National Institute on Aging‐Alzheimer's Association (NIA‐AA) criteria.[24] This approach has been used in other delirium studies.[25]

3D‐CAM Assessments

After the reference standard assessment, the 3D‐CAM was administered by trained research assistants (RAs) who were blinded to the results of the reference standard. To reduce the likelihood of fluctuations or temporal changes, all assessments were completed between 11:00 am and 2:00 pm and for each participant, within a 2‐hour time period (for example, 11:23 am to 1:23 pm).

Statistical Analyses to Determine the Best Single‐ and Two‐Item Screeners

To determine the best single 3D‐CAM item to identify delirium, the responses of the 20 individual items in the 3D‐CAM (see Supporting Table 1 in the online version of this article) were compared to the reference standard to determine their sensitivity and specificity. Similarly, an algorithm was used to generate all unique 2‐item combinations of the 20 items (190 unique pairs), which were compared to the reference. An error, no response, or an answer of I do not know by the patient was considered a positive screen for delirium. The 2‐item screeners were considered positive if 1 or both of the items were positive. Sensitivity and specificity were calculated along with 95% confidence intervals (CIs).

Subset analyses were performed to determine sensitivity and specificity of individual items and pairs of items stratified by the patient's baseline cognitive status. Two strata were createdpatients with dementia (N=56), and patients with normal baseline cognitive status or mild cognitive impairment (MCI) (N=145). We chose to group MCI with normal for 2 reasons: (1) dementia is a well‐established and strong risk factor for delirium, whereas the evidence for MCI being a risk factor for delirium is less established and (2) to achieve adequate allocation of delirious cases in both strata. Last, we report the sensitivity of altered level of consciousness (LOC), which included lethargy, stupor, coma, and hypervigilance as a single screening item for delirium in the overall sample and by cognitive status. Analyses were conducted using commercially available software (SAS version 9.3; SAS Institute, Inc., Cary, NC).

RESULTS

Characteristics of the patients are shown in Table 1. Subjects had a mean age of 84 years, 62% were female, and 28% had a baseline dementia. Forty‐two (21%) had delirium based on the clinical reference standard. Twenty (10%) had less than a high school education and 100 (49%) had at least a college education.

Sample Characteristics (N=201)
CharacteristicN (%)
  • NOTE: Abbreviations: ADL, activities of daily living; IADL, instrumental activities of daily living; MCI, mild cognitive impairment; MoCA, Montreal Cognitive Assessment; SD, standard deviation.

Age, y, mean (SD)84 (5.4)
Sex, n (%) female125 (62)
White, n (%)177 (88)
Education, n (%) 
Less than high school20 (10)
High school graduate75 (38)
College plus100 (49)
Vision interfered with interview, n (%)5 (2)
Hearing interfered with interview, n (%)18 (9)
English second language n (%)10 (5)
Charlson, mean (SD)3 (2.3)
ADL, n (% impaired)110 (55)
IADL, n (% impaired)163 (81)
MCI, n (%)50 (25)
Dementia, n (%)56 (28)
Delirium, n (%)42 (21)
MoCA, mean (SD)19 (6.6)
MoCA, median (range)20 (030)

Single Item Screens

Table 2 reports the results of single‐item screens for delirium with sensitivity, the ability to correctly identify delirium when it is present by the reference standard, and specificity, the ability to correctly identify patients without delirium when it is not present by reference standard and 95% CIs. Items are listed in descending order of sensitivity; in the case of ties, the item with the higher specificity is listed first. The screening items with the highest sensitivity for delirium are Months of the year backwards, and Four digits backwards, both with a sensitivity of 83% (95% CI: 69%‐93%). Of these 2 items, Months of the year backwards had a much better specificity of 69% (95% CI: 61%‐76%), whereas Four digits backwards had a specificity of 52% (95% CI: 44%‐60%). The item What is the day of the week? had lower sensitivity at 71% (95% CI: 55%‐84%), but excellent specificity at 92% (95% CI: 87%‐96%).

Top Ten Single‐Item Screen for Delirium (N=201)
Screen ItemScreen Positive (%)cSensitivity (95% CI)Specificity (95% CI)LRLR
  • NOTE: Number of patients with delirium=42. Abbreviations: CI, confidence interval; LR, likelihood ratio.

  • There were 20 different items and 190 possible item pairs considered.

  • Top 10 items: our primary criterion for determining this was sensitivity, with a secondary criterion of specificity in the case of ties. Items are listed in descending order on this basis.

  • Screen positive: error, do not know, or no response.

Months of the year backwards420.83 (0.69‐0.93)0.69 (0.61‐0.76)2.70.24
Four digits backwards560.83 (0.69‐0.93)0.52 (0.44‐0.60)1.720.32
What is the day of the week?210.71 (0.55‐0.84)0.92 (0.87‐0.96)9.460.31
What is the year?160.55 (0.39‐0.70)0.94 (0.9‐0.97)9.670.48
Have you felt confused during the past day?140.50 (0.34‐0.66)0.95 (0.9‐0.98)9.940.53
Days of the week backwards150.50 (0.34‐0.66)0.94 (0.89‐0.97)7.950.53
During the past day, did you see things that were not really there?110.45 (0.3‐0.61)0.97 (0.94‐0.99)17.980.56
Three digits backwards150.45 (0.3‐0.61)0.92 (0.87‐0.96)5.990.59
What type of place is this?90.38 (0.24‐0.54)0.99 (0.96‐1)30.290.63
During the past day, did you think you were not in the hospital?100.38 (0.24‐0.54)0.97 (0.94‐0.99)15.140.64

We then examined performance of single‐item screeners in patients with and without dementia (Table 3). In persons with dementia, the best single item was also Months of the year backwards, with a sensitivity of 89% (95% CI: 72%‐98%) and a specificity of 61% (95% CI: 41%‐78%). In persons with normal baseline cognition or MCI, the best performing single item was Four digits backwards, with sensitivity of 79% (95% CI: 49%‐95%) and specificity of 51% (95% CI: 42%‐60%). Months of the year backwards also performed well, with sensitivity of 71% (95% CI: 42%‐92%) and specificity of 71% (95% CI: 62%‐79%).

Top Three Single‐Item Screen for Delirium Stratified by Baseline Cognition
Test ItemNormal/MCI Patients (n=145)Dementia Patients (n=56)
Screen Positive (%)bSensitivity (95% CI)Specificity (95% CI)LRLRScreen Positive (%)bSensitivity (95% CI)Specificity (95% CI)LRLR
  • NOTE: Participants with learning problems (1) grouped with dementia and MCI participants (44) grouped with normal. Number of patients with delirium=28. Abbreviations: CI, confidence interval; LR, likelihood ratio; MCI, mild cognitive impairment.

  • Top 3 items: our primary criterion for determining this was sensitivity, with a secondary criterion of specificity in the case of ties. Items are listed in descending order on this basis.

  • Screen positive: error, do not know, or no response.

Months backwards330.71 (0.42‐0.92)0.71 (0.62‐0.79)2.460.4640.89 (0.72‐0.98)0.61 (0.41‐0.78)2.270.18
Four digits backwards520.79 (0.49‐0.95)0.51 (0.42‐0.60)1.610.42660.86 (0.67‐0.96)0.54 (0.34‐0.72)1.850.27
What is the day of the week?100.64 (0.35‐0.87)0.96 (0.91‐0.99)16.840.37500.75 (0.55‐0.89)0.75 (0.55‐0.89)30.33

Two‐Item Screens

Table 4 reports the results of 2‐item screens for delirium with sensitivity, specificity, and 95% CIs. Item pairs are listed in descending order of sensitivity following the same convention as in Table 2. The 2‐item screen with the highest sensitivity for delirium is the combination of What is the day of the week? and Months of the year backwards, with a sensitivity of 93% (95% CI: 81%‐99%) and specificity of 64% (95% CI: 56%‐70%). This screen had a positive and negative likelihood ratio (LR) of 2.59 and 0.11, respectively. The combination of What is the day of the week? and Four digits backwards had the same sensitivity 93% (95% CI: 81%‐99%), but lower specificity of 48% (95% CI: 40%‐56%). The combination of What type of place is this? (hospital) and Four digits backwards had a sensitivity of 90% (95% CI: 77%‐97%) and specificity of 51% (95% CI: 43%‐50%).

Top Ten Two‐Item Screen for Delirium (N=201)
Screen Item 1Screen Item 2Screen Positive (%)cSensitivity (95% CI)Specificity (95% CI)LRLR
  • NOTE: Number of patients with delirium=42. Abbreviations: CI, confidence interval; LR, likelihood ratio.

  • There were 20 different items and 190 possible item pairs considered.

  • Top 10 items: our primary criterion for determining this was sensitivity, with a secondary criterion of specificity in the case of ties. Items are listed in descending order on this basis.

  • Screen positive: error, do not know, or no response.

What is the day of the week?Months backwards480.93 (0.81‐0.99)0.64 (0.56‐0.70)2.590.11
What is the day of the week?Four digits backwards600.93 (0.81‐0.99)0.48 (0.4‐0.56)1.80.15
Four digits backwardsMonths backwards650.93 (0.81‐0.99)0.42 (0.34‐0.50)1.60.17
What type of place is this?Four digits backwards580.90 (0.77‐0.97)0.51 (0.43‐0.50)1.840.19
What is the year?Four digits backwards590.9 (0.77‐0.97)0.5 (0.42‐0.5)1.800.19
What is the day of the week?Three digits backwards300.88 (0.74‐0.96)0.86 (0.79‐0.90)6.090.14
What is the year?Months backwards440.88 (0.74‐0.96)0.68 (0.6‐0.75)2.750.18
What type of place is this?Months backwards430.86 (0.71‐0.95)0.69 (0.61‐0.70)2.730.21
During the past day, did you think you were not in the hospital?Months backwards430.86 (0.71‐0.95)0.69 (0.61‐0.70)2.730.21
Days of the week backwardsMonths backwards430.86 (0.71‐0.95)0.68 (0.6‐0.75)2.670.21

When subjects were stratified by baseline cognition, the best 2‐item screens for normal and MCI patients was What is the day of the week? and Four digits backwards, with 93% sensitivity (95% CI: 66%‐100%) and 50% specificity (95% CI: 42%‐59%). The best pair of items for patients with dementia (Table 5) was the same as the overall sample, What is the day of the week? and Months of the year backwards, but its performance differed with a higher sensitivity of 96% (95% CI: 82%‐100%) and lower specificity of 43% (95% CI: 24%‐63%). This same pair of items had 86% sensitivity (95% CI: 57%‐98%) and 69% (95% CI: 60%‐77%) specificity for persons with either normal cognition or MCI.

Top Three Two‐Item Screen for Normal/MCI and Persons With Dementia
Test Item 1Test Item 2Normal/MCI Patients (n=145)Dementia Patients (n=56) 
Item Positive (%)bSensitivity (95% CI)Specificity (95% CI)LRLRItem Positive (%)bSensitivity (95% CI)Specificity (95% CI)LRLR
  • NOTE: Participants with learning problems (1) grouped with dementia and MCI participants (44) grouped with normal. Number of patients with delirium=28. Abbreviations: CI, confidence interval; LR, likelihood ratio; MCI, mild cognitive impairment.

  • Top 3 items: our primary criterion for determining this was sensitivity, with a secondary criterion of specificity in the case of ties. Items are listed in descending order on this basis.

  • Screen positive: error, do not know, or no response.

What is the day of the week?Months backwards360.86 (0.57‐0.98)0.69 (0.60‐0.77)2.740.21770.96 (0.82‐1)0.43 (0.24‐0.63)1.690.08
What is the day of the week?Four digits backwards540.93 (0.66‐1)0.5 (0.42‐0.59)1.870.14770.93 (0.76‐0.99)0.39 (0.22‐0.59)1.530.18
Four digits backwardsMonths backwards610.93 (0.66‐1)0.43 (0.34‐0.52)1.620.17770.93 (0.76‐0.99)0.39 (0.22‐0.59)1.530.18

Altered Level of Consciousness as a Screener for Delirium

Altered level of consciousness (ALOC) was uncommon in our sample, with an overall prevalence of 10/201 (4.9%). When examined as a screening item for delirium, ALOC had very poor sensitivity of 19% (95% CI: 9%‐34%) but had excellent specificity 99% (95% CI: 96%‐100%). Altered LOC also demonstrated poor screening performance when stratified by cognitive status, with a sensitivity of 14% in the normal and MCI group (95% CI: 2%‐43%) and sensitivity of 21% (95% CI: 8%‐41%) in persons with dementia.

Positive and Negative Predictive Values

Although we focused on sensitivity and specificity in evaluating 1‐ and 2‐item screeners, we also examined positive and negative predictive values. These values will vary depending on the overall prevalence of delirium, which was 21% in this dataset. The best 1‐item screener, Months of the year backwards, had a positive predictive value of 31% and negative predictive value of 94%. The best 2‐item screener, Months of the year backwards with What is the day of the week?, had a positive predictive value of 41% and negative predictive value of 97% (see Supporting Tables 2 and 3 in the online version of this article) LRs for the items are in Tables 2 through 5.

DISCUSSION

Identifying simple, efficient, bedside case‐identification methods for delirium is an essential step toward improving recognition of this highly morbid syndrome in hospitalized older adults. In this study, we identified a single cognitive item, Months of the year backwards, that identified 83% of delirium cases when compared with a reference standard diagnosis. Furthermore, we identified 2 items, Months of the year backwards and What is the day of the week? which when used in combination identified 93% of delirium cases. The same 1 and 2 items also worked well in patients with dementia, in whom delirium is often missed. Although these items require further clinical validation, the development of an ultrabrief 2‐item test that identifies over 90% of delirium cases and can be completed in less than 1 minute (recently, we administered the best 2‐item screener to 20 consecutive general medicine patients over age 70 years, and it was completed in a median of 36.5 seconds), holds great potential for simplifying bedside delirium screening and improving the care of hospitalized older adults.

Our current findings both confirm and extend the emerging literature on best screening items for delirium. Sands and colleagues (2010)[26] tested a single test for delirium, Do you think (name of patient) has been more confused lately? in 21 subjects and achieved a sensitivity of 80%. Han and colleagues developed a screening tool in emergency‐department patients using the LOC question from the Richmond Agitation‐Sedation Scale and spelling the word lunch backwards, and achieved 98% sensitivity, but in a younger emergency department population with a low prevalence of dementia.[27] O'Regan et al. recently also found Months of the year backwards to be the best single‐screening item for delirium in a large sample, but only tested a 1‐item screen.[28] Our study extends these studies in several important ways by: (1) employing a rigorous clinical reference standard diagnosis of delirium, (2) having a large sample with a high prevalence of patients with dementia, (3) use of a general medical population, and (4) examining the best 2‐item screens in addition to the best single item.

Systematic intervention programs[29, 30, 31] that focus on improved delirium evaluation and management have the potential to improve patient outcomes and reduce costs. However, targeting these programs to patients with delirium has proven difficult, as only 12% to 35% of delirium cases are recognized in routine clinical practice.[11, 12, 13, 14, 15] The 1‐ and 2‐item screeners we identified could play an important role in future delirium identification. The 3D‐CAM combines high sensitivity (95%) with high specificity (94%)[16] and therefore would be an excellent choice as the second step after a positive screen. The feasibility, effectiveness, and cost of administering these screeners, followed by a brief diagnostic tool such as the 3D‐CAM, should be evaluated in future work.

Our study has noteworthy strengths, including the use of a large purposefully challenging clinical sample with advanced age that included a substantial proportion with dementia, a detailed assessment, and the testing of very brief and practical tools for bedside delirium screening.[25] This study also has several important limitations. Most importantly, we presented secondary analysis of individual items and pairs of items drawn from the 3D CAM assessment; therefore, the 2‐item bedside screen requires prospective clinical validation. The reference standard was based on the DSM‐IV, because this study was conducted prior to the release of DSM‐V. In addition, the ordering of the reference standard and 3D‐CAM assessments was not randomized due to feasibility constraints. In addition, this study was cross‐sectional, involved only a single hospital, and enrolled only older medical patients during the day shift. Our sample was older (aged 75 years and older), and a younger sample may have had a different prevalence of delirium, which could affect the positive predictive value of our ultrabrief screen. We plan to test this in a sample of patients aged 70 years and older in future studies. Finally, it should be noted that these best 1‐item and 2‐item screeners miss 17% and 7% of delirium cases, respectively. In cases where this is unacceptably high, alternative approaches might be necessary.

It is important to remember that these 1‐ and 2‐item screeners are not diagnostic tools and therefore should not be used in isolation. Optimally, they will be followed by a more specific evaluation, such as the 3D‐CAM, as part of a systematic delirium identification process. For instance, in our sample (with a delirium rate of 21%), the best 2‐item screener had a positive predictive value of 41%, meaning that positive screens are more likely to be false positives than true positives (see Supporting Tables 2 and 3 in the online version of this article).[32] Nevertheless, by reducing the total number of patients who require diagnostic instrument administration, use of these ultrabrief screeners can improve efficiency and result in a net benefit to delirium case‐identification efforts.[32]

Time has been demonstrated to be a barrier to delirium identification in previous studies, but there are likely others. These may include, for instance, staff nihilism about screening making a difference, ambiguous responsibility for delirium screening and management, unsupportive system leadership, and absent payment for these activities.[31] Moreover, it is possible that the 2‐step process we propose may create an incentive for staff to avoid positive screens as they see it creating more work for themselves. We plan to identify and address such barriers in our future work.

In conclusion, we identified a single screening item for delirium, Months of the year backwards, with 83% sensitivity, and a pair of items, Months of the year backwards and What is the day of the week?, with 93% sensitivity relative to a rigorous reference standard diagnosis. These ultrabrief screening items work well in patients with and without dementia, and should require very little training of staff. Future studies should further validate these tools, and determine their translatability and scalability into programs for systematic, widespread delirium detection. Developing efficient and accurate case identification strategies is a necessary prerequisite to appropriately target delirium management protocols, enabling healthcare systems to effectively address this costly and deadly condition.

Disclosures

Author contributionsD.M.F. conceived the study idea, participated in its design and coordination, and drafted the initial manuscript. S.K.I. contributed to the study design and conceptualization, supervision, funding, preliminary analysis, and interpretation of the data, and critical revision of the manuscript. J.G. conducted the analysis for the study and critically revised the manuscript. L.N. supervised the analysis for the study and critically revised the manuscript. R.J. contributed to the study design and critical revision of the manuscript. J.S.S. critically revised the manuscript. E.R.M. obtained funding for the study, supervised all data collection, assisted in drafting and critically revising the manuscript, and contributed to the conceptualization, design, and supervision of the study. All authors have seen and agree with the contents of the manuscript.

This work was supported by the National Institute of Aging grant number R01AG030618 and K24AG035075 to Dr. Marcantonio. Dr. Inouye's time was supported in part by grants P01AG031720, R01AG044518, and K07AG041835 from the National Institute on Aging. Dr. Inouye holds the Milton and Shirley F. Levy Family Chair (Hebrew Senior Life/Harvard Medical School). Dr. Fick is partially supported from National Institute of Nursing Research grant number R01 NR011042. Dr. Saczynski was supported in part by funding from the National Institute on Aging (K01AG33643) and from the National Heart Lung and Blood Institute (U01HL105268). The funding agencies had no role and the authors retained full autonomy in the preparation of this article. All authors and coauthors have no financial or nonfinancial conflicts of interest to disclose regarding this article.

This article was presented at the Presidential Poster Session at the American Geriatrics Society 2014 Annual Meeting in Orlando, Florida, May 14, 2014.

Delirium (acute confusion) is common in older adults and leads to poor outcomes, such as death, clinician and caregiver burden, and prolonged cognitive and functional decline.[1, 2, 3, 4] Delirium is extremely costly, with estimates ranging from $143 to $152 billion annually (2005 US$).[5, 6] Early detection and management may improve the poor outcomes and reduce costs attributable to delirium,[3, 7] yet delirium identification in clinical practice has been challenging, particularly when translating research tools to the bedside.[8, 9, 10]As a result, only 12% to 35% of delirium cases are detected in routine care, with hypoactive delirium and delirium superimposed on dementia most likely to be missed.[11, 12, 13, 14, 15]

To address these issues, we recently developed and published the three‐dimensional Confusion Assessment Method (3D‐CAM), the 3‐minute diagnostic assessment for CAM‐defined delirium.[16] The 3D‐CAM is a structured assessment tool that includes mental status testing, patient symptom probes, and guided interviewer observations for signs of delirium. 3D‐CAM items were selected through a rigorous process to determine the most informative items for the 4 CAM diagnostic features.[17] The 3D‐CAM can be completed in 3 minutes, and has 95% sensitivity and 94% specificity relative to a reference standard.[16]

Despite the capabilities of the 3D‐CAM, there are situations when even 3 minutes is too long to devote to delirium identification. Moreover, a 2‐step approach in which a sensitive ultrabrief screen is administered, followed by the 3D‐CAM in positives, may be the most efficient approach for large‐scale delirium case identification. The aim of the current study was to use the 3D‐CAM database to identify the most sensitive single item and pair of items in the diagnosis of delirium, using the reference standard in the diagnostic accuracy analysis. We hypothesized that we could identify a single item with greater than 80% sensitivity and a pair of items with greater than 90% sensitivity for detection of delirium.

METHODS

Study Sample and Design

We analyzed data from the 3D‐CAM validation study,[16] which prospectively enrolled participants from a large urban teaching hospital in Boston, Massachusetts, using a consecutive enrollment sampling strategy. Inclusion criteria were: (1) 75 years old, (2) admitted to general or geriatric medicine services, (3) able to communicate in English, (4) without terminal conditions, (5) expected hospital stay of 2 days, (6) not a previous study participant. Experienced clinicians screened patients for eligibility. If the patient lacked capacity to provide consent, the designated surrogate decision maker was contacted. The study was approved by the institutional review board.

Reference Standard Delirium Diagnosis

The reference standard delirium diagnosis was based on an extensive (45 minutes) face‐to‐face patient interview by experienced clinician assessors (neuropsychologists or advanced practice nurses), medical record review, and input from the nurse and family members. This comprehensive assessment included: (1) reason for hospital admission, hospital course, and presence of cognitive concerns, (2) family, social, and functional history, (3) Montreal Cognitive Assessment,[18] (4) Geriatric Depression Scale,[19] (5) medical record review including scoring of comorbidities using the Charlson index,[20] determination of functional status using the basic and Instrumental Activities of Daily Living,[21, 22] psychoactive medications administered, and (6) a family member interview to assess the patient's baseline cognitive status that included the Eight‐Item Interview to Differentiate Aging and Dementia,[23] to assess the presence of dementia. Using all of these data, an expert panel, including the clinical assessor, the study principal investigator (E.R.M.), a geriatrician, and an experienced neuropsychologist, adjudicated the final delirium diagnoses using Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM‐IV) criteria. The panel also adjudicated for the presence or absence of dementia and mild cognitive impairment based on National Institute on Aging‐Alzheimer's Association (NIA‐AA) criteria.[24] This approach has been used in other delirium studies.[25]

3D‐CAM Assessments

After the reference standard assessment, the 3D‐CAM was administered by trained research assistants (RAs) who were blinded to the results of the reference standard. To reduce the likelihood of fluctuations or temporal changes, all assessments were completed between 11:00 am and 2:00 pm and for each participant, within a 2‐hour time period (for example, 11:23 am to 1:23 pm).

Statistical Analyses to Determine the Best Single‐ and Two‐Item Screeners

To determine the best single 3D‐CAM item to identify delirium, the responses of the 20 individual items in the 3D‐CAM (see Supporting Table 1 in the online version of this article) were compared to the reference standard to determine their sensitivity and specificity. Similarly, an algorithm was used to generate all unique 2‐item combinations of the 20 items (190 unique pairs), which were compared to the reference. An error, no response, or an answer of I do not know by the patient was considered a positive screen for delirium. The 2‐item screeners were considered positive if 1 or both of the items were positive. Sensitivity and specificity were calculated along with 95% confidence intervals (CIs).

Subset analyses were performed to determine sensitivity and specificity of individual items and pairs of items stratified by the patient's baseline cognitive status. Two strata were createdpatients with dementia (N=56), and patients with normal baseline cognitive status or mild cognitive impairment (MCI) (N=145). We chose to group MCI with normal for 2 reasons: (1) dementia is a well‐established and strong risk factor for delirium, whereas the evidence for MCI being a risk factor for delirium is less established and (2) to achieve adequate allocation of delirious cases in both strata. Last, we report the sensitivity of altered level of consciousness (LOC), which included lethargy, stupor, coma, and hypervigilance as a single screening item for delirium in the overall sample and by cognitive status. Analyses were conducted using commercially available software (SAS version 9.3; SAS Institute, Inc., Cary, NC).

RESULTS

Characteristics of the patients are shown in Table 1. Subjects had a mean age of 84 years, 62% were female, and 28% had a baseline dementia. Forty‐two (21%) had delirium based on the clinical reference standard. Twenty (10%) had less than a high school education and 100 (49%) had at least a college education.

Sample Characteristics (N=201)
CharacteristicN (%)
  • NOTE: Abbreviations: ADL, activities of daily living; IADL, instrumental activities of daily living; MCI, mild cognitive impairment; MoCA, Montreal Cognitive Assessment; SD, standard deviation.

Age, y, mean (SD)84 (5.4)
Sex, n (%) female125 (62)
White, n (%)177 (88)
Education, n (%) 
Less than high school20 (10)
High school graduate75 (38)
College plus100 (49)
Vision interfered with interview, n (%)5 (2)
Hearing interfered with interview, n (%)18 (9)
English second language n (%)10 (5)
Charlson, mean (SD)3 (2.3)
ADL, n (% impaired)110 (55)
IADL, n (% impaired)163 (81)
MCI, n (%)50 (25)
Dementia, n (%)56 (28)
Delirium, n (%)42 (21)
MoCA, mean (SD)19 (6.6)
MoCA, median (range)20 (030)

Single Item Screens

Table 2 reports the results of single‐item screens for delirium with sensitivity, the ability to correctly identify delirium when it is present by the reference standard, and specificity, the ability to correctly identify patients without delirium when it is not present by reference standard and 95% CIs. Items are listed in descending order of sensitivity; in the case of ties, the item with the higher specificity is listed first. The screening items with the highest sensitivity for delirium are Months of the year backwards, and Four digits backwards, both with a sensitivity of 83% (95% CI: 69%‐93%). Of these 2 items, Months of the year backwards had a much better specificity of 69% (95% CI: 61%‐76%), whereas Four digits backwards had a specificity of 52% (95% CI: 44%‐60%). The item What is the day of the week? had lower sensitivity at 71% (95% CI: 55%‐84%), but excellent specificity at 92% (95% CI: 87%‐96%).

Top Ten Single‐Item Screen for Delirium (N=201)
Screen ItemScreen Positive (%)cSensitivity (95% CI)Specificity (95% CI)LRLR
  • NOTE: Number of patients with delirium=42. Abbreviations: CI, confidence interval; LR, likelihood ratio.

  • There were 20 different items and 190 possible item pairs considered.

  • Top 10 items: our primary criterion for determining this was sensitivity, with a secondary criterion of specificity in the case of ties. Items are listed in descending order on this basis.

  • Screen positive: error, do not know, or no response.

Months of the year backwards420.83 (0.69‐0.93)0.69 (0.61‐0.76)2.70.24
Four digits backwards560.83 (0.69‐0.93)0.52 (0.44‐0.60)1.720.32
What is the day of the week?210.71 (0.55‐0.84)0.92 (0.87‐0.96)9.460.31
What is the year?160.55 (0.39‐0.70)0.94 (0.9‐0.97)9.670.48
Have you felt confused during the past day?140.50 (0.34‐0.66)0.95 (0.9‐0.98)9.940.53
Days of the week backwards150.50 (0.34‐0.66)0.94 (0.89‐0.97)7.950.53
During the past day, did you see things that were not really there?110.45 (0.3‐0.61)0.97 (0.94‐0.99)17.980.56
Three digits backwards150.45 (0.3‐0.61)0.92 (0.87‐0.96)5.990.59
What type of place is this?90.38 (0.24‐0.54)0.99 (0.96‐1)30.290.63
During the past day, did you think you were not in the hospital?100.38 (0.24‐0.54)0.97 (0.94‐0.99)15.140.64

We then examined performance of single‐item screeners in patients with and without dementia (Table 3). In persons with dementia, the best single item was also Months of the year backwards, with a sensitivity of 89% (95% CI: 72%‐98%) and a specificity of 61% (95% CI: 41%‐78%). In persons with normal baseline cognition or MCI, the best performing single item was Four digits backwards, with sensitivity of 79% (95% CI: 49%‐95%) and specificity of 51% (95% CI: 42%‐60%). Months of the year backwards also performed well, with sensitivity of 71% (95% CI: 42%‐92%) and specificity of 71% (95% CI: 62%‐79%).

Top Three Single‐Item Screen for Delirium Stratified by Baseline Cognition
Test ItemNormal/MCI Patients (n=145)Dementia Patients (n=56)
Screen Positive (%)bSensitivity (95% CI)Specificity (95% CI)LRLRScreen Positive (%)bSensitivity (95% CI)Specificity (95% CI)LRLR
  • NOTE: Participants with learning problems (1) grouped with dementia and MCI participants (44) grouped with normal. Number of patients with delirium=28. Abbreviations: CI, confidence interval; LR, likelihood ratio; MCI, mild cognitive impairment.

  • Top 3 items: our primary criterion for determining this was sensitivity, with a secondary criterion of specificity in the case of ties. Items are listed in descending order on this basis.

  • Screen positive: error, do not know, or no response.

Months backwards330.71 (0.42‐0.92)0.71 (0.62‐0.79)2.460.4640.89 (0.72‐0.98)0.61 (0.41‐0.78)2.270.18
Four digits backwards520.79 (0.49‐0.95)0.51 (0.42‐0.60)1.610.42660.86 (0.67‐0.96)0.54 (0.34‐0.72)1.850.27
What is the day of the week?100.64 (0.35‐0.87)0.96 (0.91‐0.99)16.840.37500.75 (0.55‐0.89)0.75 (0.55‐0.89)30.33

Two‐Item Screens

Table 4 reports the results of 2‐item screens for delirium with sensitivity, specificity, and 95% CIs. Item pairs are listed in descending order of sensitivity following the same convention as in Table 2. The 2‐item screen with the highest sensitivity for delirium is the combination of What is the day of the week? and Months of the year backwards, with a sensitivity of 93% (95% CI: 81%‐99%) and specificity of 64% (95% CI: 56%‐70%). This screen had a positive and negative likelihood ratio (LR) of 2.59 and 0.11, respectively. The combination of What is the day of the week? and Four digits backwards had the same sensitivity 93% (95% CI: 81%‐99%), but lower specificity of 48% (95% CI: 40%‐56%). The combination of What type of place is this? (hospital) and Four digits backwards had a sensitivity of 90% (95% CI: 77%‐97%) and specificity of 51% (95% CI: 43%‐50%).

Top Ten Two‐Item Screen for Delirium (N=201)
Screen Item 1Screen Item 2Screen Positive (%)cSensitivity (95% CI)Specificity (95% CI)LRLR
  • NOTE: Number of patients with delirium=42. Abbreviations: CI, confidence interval; LR, likelihood ratio.

  • There were 20 different items and 190 possible item pairs considered.

  • Top 10 items: our primary criterion for determining this was sensitivity, with a secondary criterion of specificity in the case of ties. Items are listed in descending order on this basis.

  • Screen positive: error, do not know, or no response.

What is the day of the week?Months backwards480.93 (0.81‐0.99)0.64 (0.56‐0.70)2.590.11
What is the day of the week?Four digits backwards600.93 (0.81‐0.99)0.48 (0.4‐0.56)1.80.15
Four digits backwardsMonths backwards650.93 (0.81‐0.99)0.42 (0.34‐0.50)1.60.17
What type of place is this?Four digits backwards580.90 (0.77‐0.97)0.51 (0.43‐0.50)1.840.19
What is the year?Four digits backwards590.9 (0.77‐0.97)0.5 (0.42‐0.5)1.800.19
What is the day of the week?Three digits backwards300.88 (0.74‐0.96)0.86 (0.79‐0.90)6.090.14
What is the year?Months backwards440.88 (0.74‐0.96)0.68 (0.6‐0.75)2.750.18
What type of place is this?Months backwards430.86 (0.71‐0.95)0.69 (0.61‐0.70)2.730.21
During the past day, did you think you were not in the hospital?Months backwards430.86 (0.71‐0.95)0.69 (0.61‐0.70)2.730.21
Days of the week backwardsMonths backwards430.86 (0.71‐0.95)0.68 (0.6‐0.75)2.670.21

When subjects were stratified by baseline cognition, the best 2‐item screens for normal and MCI patients was What is the day of the week? and Four digits backwards, with 93% sensitivity (95% CI: 66%‐100%) and 50% specificity (95% CI: 42%‐59%). The best pair of items for patients with dementia (Table 5) was the same as the overall sample, What is the day of the week? and Months of the year backwards, but its performance differed with a higher sensitivity of 96% (95% CI: 82%‐100%) and lower specificity of 43% (95% CI: 24%‐63%). This same pair of items had 86% sensitivity (95% CI: 57%‐98%) and 69% (95% CI: 60%‐77%) specificity for persons with either normal cognition or MCI.

Top Three Two‐Item Screen for Normal/MCI and Persons With Dementia
Test Item 1Test Item 2Normal/MCI Patients (n=145)Dementia Patients (n=56) 
Item Positive (%)bSensitivity (95% CI)Specificity (95% CI)LRLRItem Positive (%)bSensitivity (95% CI)Specificity (95% CI)LRLR
  • NOTE: Participants with learning problems (1) grouped with dementia and MCI participants (44) grouped with normal. Number of patients with delirium=28. Abbreviations: CI, confidence interval; LR, likelihood ratio; MCI, mild cognitive impairment.

  • Top 3 items: our primary criterion for determining this was sensitivity, with a secondary criterion of specificity in the case of ties. Items are listed in descending order on this basis.

  • Screen positive: error, do not know, or no response.

What is the day of the week?Months backwards360.86 (0.57‐0.98)0.69 (0.60‐0.77)2.740.21770.96 (0.82‐1)0.43 (0.24‐0.63)1.690.08
What is the day of the week?Four digits backwards540.93 (0.66‐1)0.5 (0.42‐0.59)1.870.14770.93 (0.76‐0.99)0.39 (0.22‐0.59)1.530.18
Four digits backwardsMonths backwards610.93 (0.66‐1)0.43 (0.34‐0.52)1.620.17770.93 (0.76‐0.99)0.39 (0.22‐0.59)1.530.18

Altered Level of Consciousness as a Screener for Delirium

Altered level of consciousness (ALOC) was uncommon in our sample, with an overall prevalence of 10/201 (4.9%). When examined as a screening item for delirium, ALOC had very poor sensitivity of 19% (95% CI: 9%‐34%) but had excellent specificity 99% (95% CI: 96%‐100%). Altered LOC also demonstrated poor screening performance when stratified by cognitive status, with a sensitivity of 14% in the normal and MCI group (95% CI: 2%‐43%) and sensitivity of 21% (95% CI: 8%‐41%) in persons with dementia.

Positive and Negative Predictive Values

Although we focused on sensitivity and specificity in evaluating 1‐ and 2‐item screeners, we also examined positive and negative predictive values. These values will vary depending on the overall prevalence of delirium, which was 21% in this dataset. The best 1‐item screener, Months of the year backwards, had a positive predictive value of 31% and negative predictive value of 94%. The best 2‐item screener, Months of the year backwards with What is the day of the week?, had a positive predictive value of 41% and negative predictive value of 97% (see Supporting Tables 2 and 3 in the online version of this article) LRs for the items are in Tables 2 through 5.

DISCUSSION

Identifying simple, efficient, bedside case‐identification methods for delirium is an essential step toward improving recognition of this highly morbid syndrome in hospitalized older adults. In this study, we identified a single cognitive item, Months of the year backwards, that identified 83% of delirium cases when compared with a reference standard diagnosis. Furthermore, we identified 2 items, Months of the year backwards and What is the day of the week? which when used in combination identified 93% of delirium cases. The same 1 and 2 items also worked well in patients with dementia, in whom delirium is often missed. Although these items require further clinical validation, the development of an ultrabrief 2‐item test that identifies over 90% of delirium cases and can be completed in less than 1 minute (recently, we administered the best 2‐item screener to 20 consecutive general medicine patients over age 70 years, and it was completed in a median of 36.5 seconds), holds great potential for simplifying bedside delirium screening and improving the care of hospitalized older adults.

Our current findings both confirm and extend the emerging literature on best screening items for delirium. Sands and colleagues (2010)[26] tested a single test for delirium, Do you think (name of patient) has been more confused lately? in 21 subjects and achieved a sensitivity of 80%. Han and colleagues developed a screening tool in emergency‐department patients using the LOC question from the Richmond Agitation‐Sedation Scale and spelling the word lunch backwards, and achieved 98% sensitivity, but in a younger emergency department population with a low prevalence of dementia.[27] O'Regan et al. recently also found Months of the year backwards to be the best single‐screening item for delirium in a large sample, but only tested a 1‐item screen.[28] Our study extends these studies in several important ways by: (1) employing a rigorous clinical reference standard diagnosis of delirium, (2) having a large sample with a high prevalence of patients with dementia, (3) use of a general medical population, and (4) examining the best 2‐item screens in addition to the best single item.

Systematic intervention programs[29, 30, 31] that focus on improved delirium evaluation and management have the potential to improve patient outcomes and reduce costs. However, targeting these programs to patients with delirium has proven difficult, as only 12% to 35% of delirium cases are recognized in routine clinical practice.[11, 12, 13, 14, 15] The 1‐ and 2‐item screeners we identified could play an important role in future delirium identification. The 3D‐CAM combines high sensitivity (95%) with high specificity (94%)[16] and therefore would be an excellent choice as the second step after a positive screen. The feasibility, effectiveness, and cost of administering these screeners, followed by a brief diagnostic tool such as the 3D‐CAM, should be evaluated in future work.

Our study has noteworthy strengths, including the use of a large purposefully challenging clinical sample with advanced age that included a substantial proportion with dementia, a detailed assessment, and the testing of very brief and practical tools for bedside delirium screening.[25] This study also has several important limitations. Most importantly, we presented secondary analysis of individual items and pairs of items drawn from the 3D CAM assessment; therefore, the 2‐item bedside screen requires prospective clinical validation. The reference standard was based on the DSM‐IV, because this study was conducted prior to the release of DSM‐V. In addition, the ordering of the reference standard and 3D‐CAM assessments was not randomized due to feasibility constraints. In addition, this study was cross‐sectional, involved only a single hospital, and enrolled only older medical patients during the day shift. Our sample was older (aged 75 years and older), and a younger sample may have had a different prevalence of delirium, which could affect the positive predictive value of our ultrabrief screen. We plan to test this in a sample of patients aged 70 years and older in future studies. Finally, it should be noted that these best 1‐item and 2‐item screeners miss 17% and 7% of delirium cases, respectively. In cases where this is unacceptably high, alternative approaches might be necessary.

It is important to remember that these 1‐ and 2‐item screeners are not diagnostic tools and therefore should not be used in isolation. Optimally, they will be followed by a more specific evaluation, such as the 3D‐CAM, as part of a systematic delirium identification process. For instance, in our sample (with a delirium rate of 21%), the best 2‐item screener had a positive predictive value of 41%, meaning that positive screens are more likely to be false positives than true positives (see Supporting Tables 2 and 3 in the online version of this article).[32] Nevertheless, by reducing the total number of patients who require diagnostic instrument administration, use of these ultrabrief screeners can improve efficiency and result in a net benefit to delirium case‐identification efforts.[32]

Time has been demonstrated to be a barrier to delirium identification in previous studies, but there are likely others. These may include, for instance, staff nihilism about screening making a difference, ambiguous responsibility for delirium screening and management, unsupportive system leadership, and absent payment for these activities.[31] Moreover, it is possible that the 2‐step process we propose may create an incentive for staff to avoid positive screens as they see it creating more work for themselves. We plan to identify and address such barriers in our future work.

In conclusion, we identified a single screening item for delirium, Months of the year backwards, with 83% sensitivity, and a pair of items, Months of the year backwards and What is the day of the week?, with 93% sensitivity relative to a rigorous reference standard diagnosis. These ultrabrief screening items work well in patients with and without dementia, and should require very little training of staff. Future studies should further validate these tools, and determine their translatability and scalability into programs for systematic, widespread delirium detection. Developing efficient and accurate case identification strategies is a necessary prerequisite to appropriately target delirium management protocols, enabling healthcare systems to effectively address this costly and deadly condition.

Disclosures

Author contributionsD.M.F. conceived the study idea, participated in its design and coordination, and drafted the initial manuscript. S.K.I. contributed to the study design and conceptualization, supervision, funding, preliminary analysis, and interpretation of the data, and critical revision of the manuscript. J.G. conducted the analysis for the study and critically revised the manuscript. L.N. supervised the analysis for the study and critically revised the manuscript. R.J. contributed to the study design and critical revision of the manuscript. J.S.S. critically revised the manuscript. E.R.M. obtained funding for the study, supervised all data collection, assisted in drafting and critically revising the manuscript, and contributed to the conceptualization, design, and supervision of the study. All authors have seen and agree with the contents of the manuscript.

This work was supported by the National Institute of Aging grant number R01AG030618 and K24AG035075 to Dr. Marcantonio. Dr. Inouye's time was supported in part by grants P01AG031720, R01AG044518, and K07AG041835 from the National Institute on Aging. Dr. Inouye holds the Milton and Shirley F. Levy Family Chair (Hebrew Senior Life/Harvard Medical School). Dr. Fick is partially supported from National Institute of Nursing Research grant number R01 NR011042. Dr. Saczynski was supported in part by funding from the National Institute on Aging (K01AG33643) and from the National Heart Lung and Blood Institute (U01HL105268). The funding agencies had no role and the authors retained full autonomy in the preparation of this article. All authors and coauthors have no financial or nonfinancial conflicts of interest to disclose regarding this article.

This article was presented at the Presidential Poster Session at the American Geriatrics Society 2014 Annual Meeting in Orlando, Florida, May 14, 2014.

References
  1. Witlox J, Eurelings LS, Jonghe JF, Kalisvaart KJ, Eikelenboom P, Gool WA. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta‐analysis. JAMA. 2010;304(4):443451.
  2. Saczynski JS, Marcantonio ER, Quach L, et al. Cognitive trajectories after postoperative delirium. N Engl J Med. 2012;367(1):3039.
  3. Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet. 2014;383:911922.
  4. Fick DM, Steis MR, Waller JL, Inouye SK. Delirium superimposed on dementia is associated with prolonged length of stay and poor outcomes in hospitalized older adults. J Hosp Med. 2013;8(9):500505.
  5. Leslie DL, Marcantonio ER, Zhang Y, Leo‐Summers L, Inouye SK. One‐year health care costs associated with delirium in the elderly population. Arch Intern Med. 2008;168(1):2732.
  6. Leslie DL, Inouye SK. The importance of delirium: Economic and societal costs. J Am Geriatr Soc. 2011;59(suppl 2):S241S243.
  7. Marcantonio ER. Delirium. Ann Intern Med. 2011;154(11):ITC6.
  8. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50.
  9. Rice KL, Bennett MJ, Clesi T, Linville L. Mixed‐methods approach to understanding nurses' clinical reasoning in recognizing delirium in hospitalized older adults. J Contin Educ Nurs. 2014;45:1–13.
  10. Yanamadala M, Wieland D, Heflin MT. Educational interventions to improve recognition of delirium: a systematic review. J Am Geriatr Soc. 2013;61(11):19831993.
  11. Steis MR, Fick DM. Delirium superimposed on dementia: accuracy of nurse documentation. J Gerontol Nurs. 2012;38(1):3242.
  12. Lemiengre J, Nelis T, Joosten E, et al. Detection of delirium by bedside nurses using the confusion assessment method. J Am Geriatr Soc. 2006;54:685689.
  13. Milisen K, Foreman MD, Wouters B, et al. Documentation of delirium in elderly patients with hip fracture. J Gerontol Nurs. 2002;28(11):2329.
  14. Kales HC, Kamholz BA, Visnic SG, Blow FC. Recorded delirium in a national sample of elderly inpatients: potential implications for recognition. J Geriatr Psychiatry Neurol. 2003;16(1):3238.
  15. Saczynski JS, Kosar CM, Xu G, et al. A tale of two methods: chart and interview methods for identifying delirium. J Am Geriatr Soc. 2014;62(3):518524.
  16. Marcantonio E, Ngo L, Jones R, et al. 3D‐CAM: Derivation and validation of a 3‐minute diagnostic interview for CAM‐defined delirium: a cross‐sectional diagnostic test study. Ann Intern Med. 2014;161(8):554561.
  17. Yang FM, Jones RN, Inouye SK, et al. Selecting optimal screening items for delirium: an application of item response theory. BMC Med Res Methodol. 2013;13:8.
  18. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695699.
  19. Yesavage JA. Geriatric Depression Scale. Psychopharmacol Bull. 1988;24(4):709711.
  20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373383.
  21. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914919.
  22. Lawton MP, Brody EM. Assessment of older people: self‐maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179186.
  23. Galvin J, Roe C, Powlishta K, et al. The AD8: a brief informant interview to detect dementia. Neurology. 2005;65(4):559564.
  24. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263269.
  25. Neufeld KJ, Nelliot A, Inouye SK, et al. Delirium diagnosis methodology used in research: a survey‐based study. Am J Geriatr Psychiatry. 2014;22(12):15131521.
  26. Sands M, Dantoc B, Hartshorn A, Ryan C, Lujic S. Single Question in Delirium (SQiD): testing its efficacy against psychiatrist interview, the Confusion Assessment Method and the Memorial Delirium Assessment Scale. Palliat Med. 2010;24(6):561565.
  27. Han JH, Wilson A, Vasilevskis EE, et al. Diagnosing delirium in older emergency department patients: validity and reliability of the delirium triage screen and the brief confusion assessment method. Ann Emerg Med. 2013;62(5):457465.
  28. O'Regan NA, Ryan DJ, Boland E, et al. Attention! A good bedside test for delirium? J Neurol Neurosurg Psychiatry. 2014;85(10):11221131.
  29. Bergmann MA, Murphy KM, Kiely DK, Jones RN, Marcantonio ER. A model for management of delirious postacute care patients. J Am Geriatr Soc. 2005;53(10):18171825.
  30. Fick DM, Steis MR, Mion LC, Walls JL. Computerized decision support for delirium superimposed on dementia in older adults: a pilot study. J Gerontol Nurs. 2011;37(4):3947.
  31. Yevchak AM, Fick DM, McDowell J, et al. Barriers and facilitators to implementing delirium rounds in a clinical trial across three diverse hospital settings. Clin Nurs Res. 2014;23(2):201215.
  32. Meehl PE, Rosen A. Antecedent probability and the efficiency of psychometric signs, patterns, or cutting scores. Psychol Bull. 1955;52(3):194.
References
  1. Witlox J, Eurelings LS, Jonghe JF, Kalisvaart KJ, Eikelenboom P, Gool WA. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta‐analysis. JAMA. 2010;304(4):443451.
  2. Saczynski JS, Marcantonio ER, Quach L, et al. Cognitive trajectories after postoperative delirium. N Engl J Med. 2012;367(1):3039.
  3. Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet. 2014;383:911922.
  4. Fick DM, Steis MR, Waller JL, Inouye SK. Delirium superimposed on dementia is associated with prolonged length of stay and poor outcomes in hospitalized older adults. J Hosp Med. 2013;8(9):500505.
  5. Leslie DL, Marcantonio ER, Zhang Y, Leo‐Summers L, Inouye SK. One‐year health care costs associated with delirium in the elderly population. Arch Intern Med. 2008;168(1):2732.
  6. Leslie DL, Inouye SK. The importance of delirium: Economic and societal costs. J Am Geriatr Soc. 2011;59(suppl 2):S241S243.
  7. Marcantonio ER. Delirium. Ann Intern Med. 2011;154(11):ITC6.
  8. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50.
  9. Rice KL, Bennett MJ, Clesi T, Linville L. Mixed‐methods approach to understanding nurses' clinical reasoning in recognizing delirium in hospitalized older adults. J Contin Educ Nurs. 2014;45:1–13.
  10. Yanamadala M, Wieland D, Heflin MT. Educational interventions to improve recognition of delirium: a systematic review. J Am Geriatr Soc. 2013;61(11):19831993.
  11. Steis MR, Fick DM. Delirium superimposed on dementia: accuracy of nurse documentation. J Gerontol Nurs. 2012;38(1):3242.
  12. Lemiengre J, Nelis T, Joosten E, et al. Detection of delirium by bedside nurses using the confusion assessment method. J Am Geriatr Soc. 2006;54:685689.
  13. Milisen K, Foreman MD, Wouters B, et al. Documentation of delirium in elderly patients with hip fracture. J Gerontol Nurs. 2002;28(11):2329.
  14. Kales HC, Kamholz BA, Visnic SG, Blow FC. Recorded delirium in a national sample of elderly inpatients: potential implications for recognition. J Geriatr Psychiatry Neurol. 2003;16(1):3238.
  15. Saczynski JS, Kosar CM, Xu G, et al. A tale of two methods: chart and interview methods for identifying delirium. J Am Geriatr Soc. 2014;62(3):518524.
  16. Marcantonio E, Ngo L, Jones R, et al. 3D‐CAM: Derivation and validation of a 3‐minute diagnostic interview for CAM‐defined delirium: a cross‐sectional diagnostic test study. Ann Intern Med. 2014;161(8):554561.
  17. Yang FM, Jones RN, Inouye SK, et al. Selecting optimal screening items for delirium: an application of item response theory. BMC Med Res Methodol. 2013;13:8.
  18. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695699.
  19. Yesavage JA. Geriatric Depression Scale. Psychopharmacol Bull. 1988;24(4):709711.
  20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373383.
  21. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914919.
  22. Lawton MP, Brody EM. Assessment of older people: self‐maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179186.
  23. Galvin J, Roe C, Powlishta K, et al. The AD8: a brief informant interview to detect dementia. Neurology. 2005;65(4):559564.
  24. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263269.
  25. Neufeld KJ, Nelliot A, Inouye SK, et al. Delirium diagnosis methodology used in research: a survey‐based study. Am J Geriatr Psychiatry. 2014;22(12):15131521.
  26. Sands M, Dantoc B, Hartshorn A, Ryan C, Lujic S. Single Question in Delirium (SQiD): testing its efficacy against psychiatrist interview, the Confusion Assessment Method and the Memorial Delirium Assessment Scale. Palliat Med. 2010;24(6):561565.
  27. Han JH, Wilson A, Vasilevskis EE, et al. Diagnosing delirium in older emergency department patients: validity and reliability of the delirium triage screen and the brief confusion assessment method. Ann Emerg Med. 2013;62(5):457465.
  28. O'Regan NA, Ryan DJ, Boland E, et al. Attention! A good bedside test for delirium? J Neurol Neurosurg Psychiatry. 2014;85(10):11221131.
  29. Bergmann MA, Murphy KM, Kiely DK, Jones RN, Marcantonio ER. A model for management of delirious postacute care patients. J Am Geriatr Soc. 2005;53(10):18171825.
  30. Fick DM, Steis MR, Mion LC, Walls JL. Computerized decision support for delirium superimposed on dementia in older adults: a pilot study. J Gerontol Nurs. 2011;37(4):3947.
  31. Yevchak AM, Fick DM, McDowell J, et al. Barriers and facilitators to implementing delirium rounds in a clinical trial across three diverse hospital settings. Clin Nurs Res. 2014;23(2):201215.
  32. Meehl PE, Rosen A. Antecedent probability and the efficiency of psychometric signs, patterns, or cutting scores. Psychol Bull. 1955;52(3):194.
Issue
Journal of Hospital Medicine - 10(10)
Issue
Journal of Hospital Medicine - 10(10)
Page Number
645-650
Page Number
645-650
Publications
Publications
Article Type
Display Headline
Preliminary development of an ultrabrief two‐item bedside test for delirium
Display Headline
Preliminary development of an ultrabrief two‐item bedside test for delirium
Sections
Article Source

© 2015 Society of Hospital Medicine

Disallow All Ads
Correspondence Location
Address for correspondence and reprint requests: Donna M. Fick, PhD, Distinguished Professor, College of Nursing, Penn State University, Health and Human Development East, University Park, PA 16802; Telephone: 814‐865‐9325; Fax: 814‐865‐3779; E‐mail: dmf21@psu.edu
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Article PDF Media
Media Files

Opioids and Opioid‐Related Adverse Events

Article Type
Changed
Sun, 05/21/2017 - 15:07
Display Headline
Opioid utilization and opioid‐related adverse events in nonsurgical patients in US hospitals

Recent reports have drawn attention to the high and increasing rates of opioid prescribing and overdose‐related deaths in the United States.[1, 2, 3, 4, 5, 6, 7, 8, 9] These studies have focused on community‐based and emergency department prescribing, leaving prescribing practices in the inpatient setting unexamined. Given that pain is a frequent complaint in hospitalized patients, and that the Joint Commission mandates assessing pain as a vital sign, hospitalization is potentially a time of heightened use of such medications and could significantly contribute to nosocomial complications and subsequent outpatient use.[10] Variation in prescribing practices, unrelated to patient characteristics, could be a marker of inappropriate prescribing practices and poor quality of care.

Using a large, nationally representative cohort of admissions from July 2009 to June 2010, we sought to determine patterns and predictors of opioid utilization in nonsurgical admissions to US medical centers, hospital variation in use, and the association between hospital‐level use and the risk of opioid‐related adverse events. We hypothesized that hospitals with higher rates of opioid use would have an increased risk of an opioid‐related adverse event per patient exposed.

METHODS

Setting and Patients

We conducted a retrospective cohort study using data from 286 US nonfederal acute‐care facilities contributing to the database maintained by Premier (Premier Healthcare Solutions, Inc., Charlotte, NC). This database, created to measure healthcare utilization and quality of care, is drawn from voluntarily participating hospitals and contains data on approximately 1 in every 4 discharges nationwide.[11] Participating hospitals are similar in geographic distribution and metropolitan (urban/rural) status to hospitals nationwide, although large, nonteaching hospitals are slightly overrepresented in Premier. The database contains patient demographics, International Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9‐CM) codes, hospital demographics, and a date‐stamped log of all charges during the course of each hospitalization, including diagnostic tests, therapeutic treatments, and medications with dose and route of administration. The study was approved by the institutional review board at Beth Israel Deaconess Medical Center and granted a waiver of informed consent.

We studied a cohort of all adult nonsurgical admissions to participating hospitals from July 1, 2009, through June 30, 2010. We chose to study nonsurgical admissions, as patients undergoing surgical procedures have a clear indication for, and almost always receive, opioid pain medications. We defined a nonsurgical admission as an admission in which there were no charges for operating‐room procedures (including labor and delivery) and the attending of record was not a surgeon. We excluded admissions with unknown gender, since this is a key demographic variable, and admissions with a length of stay greater than 365 days, as these admissions are not representative of the typical admission to an acute‐care hospital. At the hospital level, we excluded hospitals contributing <100 admissions owing to resultant lack of precision in corresponding hospital prescribing rates, and hospitals that did not prescribe the full range of opioid medications (these hospitals had charges for codeine only), as these facilities seemed likely to have unusual limitations on prescribing or incomplete data capture.

Opioid Exposure

We defined opioid exposure as presence of 1 charge for an opioid medication during the admission. Opioid medications included morphine, hydrocodone, hydromorphone, oxycodone, fentanyl, meperidine, methadone, codeine, tramadol, buprenorphine, levorphanol, oxymorphone, pentazocine, propoxyphene, tapentadol, butorphanol, dezocine, and nalbuphine. We grouped the last 9 into an other category owing to infrequent use and/or differing characteristics from the main opioid drug types, such as synthetic, semisynthetic, and partial agonist qualities.

Severe Opioid‐Related Adverse Events

We defined severe opioid‐related adverse events as either naloxone exposure or an opioid‐related adverse drug event diagnosis code. Naloxone use in an adult patient exposed to opioids is one of the Institute for Healthcare Improvement's Trigger Tools for identifying adverse drug events[12] and previously has been demonstrated to have high positive predictive value for a confirmed adverse drug event.[13] We defined naloxone exposure as presence of 1 charge for naloxone. We excluded charges on hospital day 1 to focus on nosocomial events. We defined opioid‐related adverse drug events using ICD‐9‐CM diagnosis codes for poisoning by opioids (overdose, wrong substance given, or taken in error; ICD‐9‐CM 965.02, 965.09, E850.1, E850.2) and drugs causing adverse effects in therapeutic use (ICD‐9‐CM E935.1, E935.2), as specified in prior analyses by the Agency for Healthcare Research and Quality (AHRQ).[14, 15] To avoid capturing adverse events associated with outpatient use, we required the ICD‐9‐CM code to be qualified as not present on admission using the present on admission indicator required by the Centers for Medicare and Medicaid Services for all discharge diagnosis codes since 2008.[16]

Covariates of Interest

We were interested in the relationship between both patient and hospital characteristics and opioid exposure. Patient characteristics of interest included (1) demographic variables, such as age, sex, race (self‐reported by patients at the time of admission), marital status, and payer; (2) whether or not the patient spent any time in the intensive care unit (ICU); (3) comorbidities, identified via ICD‐9‐CM secondary diagnosis codes and diagnosis‐related groups using Healthcare Cost and Utilization Project Comorbidity Software, version 3.7, based on the work of Elixhauser et al[17, 18]; (4) primary ICD‐9‐CM discharge diagnosis groupings, selected based on hypothesized associations with receipt of opioids, and based on the Clinical Classifications Software (CCS)a diagnosis and procedure categorization scheme maintained by the AHRQ, and defined in the Appendix[19]; (5) and nonoperating‐room‐based procedures potentially necessitating opioids during the admission, selected from the 50 most common ICD‐9‐CM procedure codes in our cohort and grouped as cardiovascular procedures (catheterization and insertion of vascular stents), gastrointestinal procedures (upper and lower endoscopy), and mechanical ventilation, further defined in the Appendix. Hospital characteristics of interest included number of beds, population served (urban vs rural), teaching status, and US census region (Northeast, Midwest, South, West).

Statistical Analysis

We calculated the percent of admissions with exposure to any opioid and the percent exposed to each opioid, along with the total number of different opioid medications used during each admission. We also calculated the percent of admissions with parenteral administration and the percent of admissions with oral administration, among those exposed to the individual categories, and in aggregate. Because medications after discharge were unavailable in Premier's dataset, we report the percent of patients with a charge for opioids on the day of discharge.

We determined the daily dose of an opioid by taking the sum of the doses for that opioid charged on a given day. The average daily dose of an opioid was determined by taking the sum of the daily doses and dividing by the number of days on which 1 dose was charged. To facilitate comparison, all opioids, with the exception of those for which standard equivalences are unavailable (tramadol, other opioid category, oral fentanyl, epidural route for all), were converted to oral morphine equivalents using a standard equivalence conversion table.[20, 21] We excluded from our dosage calculations those charges for which standard morphine equivalence was unavailable, or for which dosage was missing. We also excluded from our dosage calculations any dose that was >3 standard deviations (SD) above the mean dose for that opioid, as such extreme values seemed physiologically implausible and more likely to be a data entry error that could lead to significant overestimation of the mean for that opioid.

All multivariable models used a generalized estimating equation (GEE) via the genmod procedure in SAS, with a Poisson distribution error term and a log link, controlling for repeated patient admissions with an autoregressive correlation structure.

To identify independent predictors of opioid receipt, we used a GEE model of opioid receipt where all patient and hospital characteristics listed in Table 1 were included as independent variables.

Patient and Hospital Characteristics
Patient characteristics, N=1,139,419N%
  • NOTE: Abbreviations: AIDS, acquired immune deficiency syndrome; CHF, congestive heart failure; DM, diabetes mellitus; GI, gastrointestinal; ICU, intensive care unit; PVD, peripheral vascular disease; RA, rheumatoid arthritis; US, United States.

  • Patient characteristics presented for each admission do not take into account multiple admissions of the same patient.

  • Pain‐related diagnoses include abdominal pain, headache, nonspecific chest pain, pancreatic disorders, musculoskeletal back problems, and calculus of urinary tract.

Age group, y  
182437,4643
253466,5416
3544102,7019
4554174,83015
5564192,57017
6574196,40717
75+368,90632
Sex  
Male527,06246
Female612,35754
Race  
White711,99362
Black176,99316
Hispanic54,4065
Other196,02717
Marital status  
Married427,64838
Single586,34351
Unknown/other125,42811
Primary insurance  
Private/commercial269,72524
Medicare traditional502,30144
Medicare managed care126,34411
Medicaid125,02511
Self‐pay/other116,02410
ICU care  
No1,023,02790
Yes116,39210
Comorbidities  
AIDS57241
Alcohol abuse79,6337
Deficiency anemias213,43719
RA/collagen vascular disease35,2103
Chronic blood‐loss anemia10,8601
CHF190,08517
Chronic pulmonary disease285,95425
Coagulopathy48,5134
Depression145,55313
DM without chronic complications270,08724
DM with chronic complications70,7326
Drug abuse66,8866
Hypertension696,29961
Hypothyroidism146,13613
Liver disease38,1303
Lymphoma14,0321
Fluid and electrolyte disorders326,57629
Metastatic cancer33,4353
Other neurological disorders124,19511
Obesity118,91510
Paralysis38,5843
PVD77,3347
Psychoses101,8569
Pulmonary circulation disease52,1065
Renal failure175,39815
Solid tumor without metastasis29,5943
Peptic ulcer disease excluding bleeding5360
Valvular disease86,6168
Weight loss45,1324
Primary discharge diagnoses  
Cancer19,1682
Musculoskeletal injuries16,7981
Pain‐related diagnosesb101,5339
Alcohol‐related disorders16,7771
Substance‐related disorders13,6971
Psychiatric disorders41,1534
Mood disorders28,7613
Schizophrenia and other psychotic disorders12,3921
Procedures  
Cardiovascular procedures59,9015
GI procedures31,2243
Mechanical ventilation78531
Hospital characteristics, N=286  
Number of beds  
<20010336
2013006322
3015008128
>5003914
Population served  
Urban22579
Rural6121
Teaching status  
Nonteaching20772
Teaching7928
US Census region  
Northeast4716
Midwest6322
South11540
West6121

To assess hospital variation in opioid prescribing after adjusting for patient characteristics, we used a GEE model of opioid receipt, controlling for all patient characteristics listed in Table 1. We then took the mean of the predicted probabilities of opioid receipt for the patients within each hospital in our cohort to derive the hospital prescribing rate adjusted for patient characteristics. We report the mean, SD, and range of the prescribing rates for the hospitals in our cohort before and after adjustment for patient characteristics.

To assess whether patients admitted to hospitals with higher rates of opioid prescribing have higher relative risk of severe opioid‐related adverse events, we stratified hospitals into opioid‐prescribing rate quartiles and compared the rates of opioid‐related adverse eventsboth overall and among opioid exposedbetween quartiles. To adjust for patient characteristics, we used a GEE model in which severe opioid‐related adverse event (yes/no) was the dependent variable and hospital‐prescribing rate quartile and all patient characteristics in Table 1 were independent variables. We also performed a sensitivity analysis in which we assessed the association between hospital prescribing‐rate quartile and the individual components of our composite outcome. Our results were qualitatively unchanged using this approach, and only the results of our main analysis are presented.

All analyses were carried out using SAS software, version 9.2 (SAS Institute Inc., Cary, NC).

RESULTS

Patient Admission Characteristics

There were 3,190,934 adult admissions to 300 acute‐care hospitals during our study period. After excluding admissions with a length of stay >365 days (n=25), missing patient sex (n=17), and charges for operating‐room procedures or a surgical attending of record (n=2,018,553), 1,172,339 admissions were available for analysis. There were 12 hospitals with incomplete opioid‐prescribing data (n=32,794) and 2 hospitals that contributed <100 admissions each (n=126), leaving 1,139,419 admissions in 286 hospitals in our analytic cohort. The median age of the cohort was 64 years (interquartile range, 4979 years), and 527,062 (46%) were men. Table 1 shows the characteristics of the admissions in the cohort.

Rate, Route, and Dose of Opioid Exposures

Overall, there were 576,373 (51%) admissions with charges for opioid medications. Among those exposed, 244,760 (43%) had charges for multiple opioids during the admission; 172,090 (30%) had charges for 2 different opioids; and 72,670 (13%) had charges for 3 different opioids. Table 2 shows the percent exposed to each opioid, the percent of exposed with parenteral and oral routes of administration, and the mean daily dose received in oral morphine equivalents.

Rate of Exposure, Route of Administration, and Average Dose of Opioids Received, Overall and by Opioid (N=1,139,419)
 ExposedParenteral AdministrationOral AdministrationDose Received, in Oral Morphine Equivalents
 N%aN%bN%bMeanSDc
  • NOTE: Abbreviations: SD, standard deviation.

  • Percentages exposed to different opioids add up to more than total receiving any opioid since patients may be exposed to >1 opioid during their hospitalization.

  • Denominator is the number exposed. Percentages may add up to100% owing to missing route information or receipt of both parenteral and oral routes, respectively.

  • On days on which opioids were received. Charges for tramadol, other category opioids, oral fentanyl (0.7% of fentanyl charges), and epidural‐route opioids (3.5% of fentanyl charges, 0.1% of morphine charges, and 0.1% of hydromorphone charges) were not included in dosage calculations due to lack of standard conversion factor to morphine equivalents. Charges with missing dose were also excluded (2% of total remaining opioid charges). Includes the following opioids: buprenorphine, levorphanol, oxymorphone, pentazocine, propoxyphene, tapentadol, butorphanol, dezocine, and nalbuphine.

All opioids576,37351378,77166371,7966568185
Morphine224,81120209,0409321,6451040121
Hydrocodone162,5581400160,941991412
Hydromorphone146,23613137,9369416,05211113274
Oxycodone126,7331100125,033992637
Fentanyl105,0529103,1139864116475
Tramadol35,57030035,570100  
Meperidine24,850224,3989851523634
Methadone15,3021370214,78197337384
Codeine22,8182178122,18397915
Other45,469458211339,61887  

Among the medications/routes for which conversion to morphine equivalents was possible, dosage was missing in 39,728 out of 2,294,673 opioid charges (2%). The average daily dose received in oral morphine equivalents was 68 mg. A total dose of 50 mg per day was received in 39% of exposed, and a total dose of 100 mg per day was received in 23% of exposed. Among those exposed, 52% (26% of overall admissions) had charges for opioids on the day of discharge.

Rates of Opioid Use by Patient and Hospital Characteristics

Table 3 reports the association between admission characteristics and opioid use. Use was highest in patients between the ages of 25 and 54 years. Although use declined with age, 44% of admissions age 65 years had charges for opioid medication. After adjustment for patient demographics, comorbidities, and hospital characteristics, opioid use was more common in females than males, those age 2554 years compared with those older and younger, those of Caucasian race compared with non‐Caucasian race, and those with Medicare or Medicaid primary insurance. Among the primary discharge diagnoses, patients with musculoskeletal injuries, various specific and nonspecific pain‐related diagnoses, and cancer were significantly more likely to receive opioids than patients without these diagnoses, whereas patients with alcohol‐related disorders and psychiatric disorders were significantly less likely to receive opioids than patients without these diagnoses. Patients admitted to hospitals in the Midwest, South, and West were significantly more likely to receive opioid medications than patients in the Northeast.

Association Between Admission Characteristics and Opioid Use (N=1,139,419)
 Exposed, N=576,373Unexposed, N=563,046% ExposedAdjusted RRa95% CI
  • NOTE: Abbreviations: AIDS, acquired immune deficiency syndrome; CHF, congestive heart failure; CI, confidence interval; DM, diabetes mellitus; GEE, generalized estimating equation; GI, gastrointestinal; ICU, intensive care unit; PVD, peripheral vascular disease; RA, rheumatoid arthritis; ref, reference; RR, relative risk; US, United States.

  • Multivariable GEE model used to account for multiple admissions of the same patient, with simultaneous control for all variables listed in this table.

  • For comorbidities, primary discharge diagnoses, and procedures, the reference group is absence of that condition or procedure.

  • Pain‐related diagnoses include abdominal pain, headache, nonspecific chest pain, pancreatic disorders, musculoskeletal back problems, and calculus of urinary tract.

Patient characteristics     
Age group, y     
182417,36020,10446(ref) 
253437,79328,748571.171.16‐1.19
354460,71241,989591.161.15‐1.17
4554103,79871,032591.111.09‐1.12
5564108,25684,314561.000.98‐1.01
657498,11098,297500.840.83‐0.85
75+150,344218,562410.710.70‐0.72
Sex     
Male255,315271,74748(ref) 
Female321,058291,299521.111.10‐1.11
Race     
White365,107346,88651(ref) 
Black92,01384,980520.930.92‐0.93
Hispanic27,59226,814510.940.93‐0.94
Other91,661104,366470.930.92‐0.93
Marital status     
Married222,912204,73652(ref) 
Single297,742288,601511.000.99‐1.01
Unknown/other55,71969,709440.940.93‐0.95
Primary insurance     
Private/commercial143,954125,77153(ref) 
Medicare traditional236,114266,187471.101.09‐1.10
Medicare managed care59,10467,240471.111.11‐1.12
Medicaid73,58351,442591.131.12‐1.13
Self‐pay/other63,61852,406551.031.02‐1.04
ICU care     
No510,654512,37350(ref) 
Yes65,71950,673561.021.01‐1.03
Comorbiditiesb     
AIDS36552069641.091.07‐1.12
Alcohol abuse35,11244,521440.920.91‐0.93
Deficiency anemias115,84297,595541.081.08‐1.09
RA/collagen vascular disease22,51912,691641.221.21‐1.23
Chronic blood‐loss anemia64444416591.041.02‐1.05
CHF88,895101,190470.990.98‐0.99
Chronic pulmonary disease153,667132,287541.081.08‐1.08
Coagulopathy25,80222,711531.031.02‐1.04
Depression83,05162,502571.081.08‐1.09
DM without chronic complications136,184133,903500.990.99‐0.99
DM with chronic complications38,69632,036551.041.03‐1.05
Drug abuse37,20229,684561.141.13‐1.15
Hypertension344,718351,581500.980.97‐0.98
Hypothyroidism70,78675,350480.990.99‐0.99
Liver disease24,06714,063631.151.14‐1.16
Lymphoma77276305551.161.14‐1.17
Fluid and electrolyte disorders168,814157,762521.041.03‐1.04
Metastatic cancer23,9209515721.401.39‐1.42
Other neurological disorders51,09173,104410.870.86‐0.87
Obesity69,58449,331591.051.04‐1.05
Paralysis17,49721,087450.970.96‐0.98
PVD42,17635,158551.111.11‐1.12
Psychoses38,63863,218380.910.90‐0.92
Pulmonary circulation disease26,65625,450511.051.04‐1.06
Renal failure86,56588,833491.011.01‐1.02
Solid tumor without metastasis16,25813,336551.141.13‐1.15
Peptic ulcer disease excluding bleeding376160701.121.07‐1.18
Valvular disease38,39648,220440.930.92‐0.94
Weight loss25,72419,408571.091.08‐1.10
Primary discharge diagnosesb     
Cancer13,9865182731.201.19‐1.21
Musculoskeletal injuries14,6382160872.022.002.04
Pain‐related diagnosesc64,65636,877641.201.20‐1.21
Alcohol‐related disorders342513,352200.460.44‐0.47
Substance‐related disorders86805017631.031.01‐1.04
Psychiatric disorders725333,900180.370.36‐0.38
Mood disorders594322,81821  
Schizophrenia and other psychotic disorders131011,08211  
Proceduresb     
Cardiovascular procedures50,9978904851.801.79‐1.81
GI procedures27,2064018871.701.69‐1.71
Mechanical ventilation53412512681.371.34‐1.39
Hospital characteristics     
Number of beds     
<200100,90088,43953(ref) 
201300104,21399,995510.950.95‐0.96
301500215,340209,104510.940.94‐0.95
>500155,920165,508490.960.95‐0.96
Population served     
Urban511,727506,80350(ref) 
Rural64,64656,243530.980.97‐0.99
Teaching status     
Nonteaching366,623343,58152(ref) 
Teaching209,750219,465491.000.99‐1.01
US Census region     
Northeast99,377149,44640(ref) 
Midwest123,194120,322511.26(1.25‐1.27)
South251,624213,029541.33(1.33‐1.34)
West102,17880,249561.37(1.36‐1.38)

Variation in Opioid Prescribing

Figure 1 shows the histograms of hospital opioid prescribing rate for the 286 hospitals in our cohort (A) before and (B) after adjustment for patient characteristics. The observed rates ranged from 5% in the lowest‐prescribing hospital to 72% in the highest‐prescribing hospital, with a mean (SD) of 51% (10%). After adjusting for patient characteristics, the adjusted opioid‐prescribing rates ranged from 33% to 64%, with a mean (SD) of 50% (4%).

Figure 1
Histograms of hospital opioid prescribing rate (A) before and (B) after adjustment for patient characteristics.

Severe Opioid‐Related Adverse Events

Among admissions with opioid exposure (n=576,373), naloxone use occurred in 2345 (0.41%) and opioid‐related adverse drug events in 1174 (0.20%), for a total of 3441 (0.60%) severe opioid‐related adverse events (some patients experienced both). Table 4 reports the opioid exposure and severe opioid‐related adverse‐event rates within hospital opioid‐prescribing rate quartiles, along with the adjusted association between the hospital opioid‐prescribing rate quartile and severe opioid‐related adverse events. After adjusting for patient characteristics, the relative risk of a severe opioid‐related adverse event was significantly greater in hospitals with higher opioid‐prescribing rates, both overall and among opioid exposed.

Association Between Hospital Opioid‐Prescribing Rate Quartile and Risk of an Opioid‐Related Adverse Event
QuartileNo. of PatientsOpioid Exposed, n (%)Opioid‐Related Adverse Events, n (%)Adjusted RR in All Patients, RR (95% CI), N=1,139,419aAdjusted RR in Opioid Exposed, RR (95% CI), N=576,373a
  • NOTE: Abbreviations: CI, confidence interval; GEE, generalized estimating equation; ref, reference; ref, reference; RR, relative risk.

  • Adjusted for repeated admissions and patient characteristics presented in Table 1 using a multivariable GEE model with a Poisson error term distribution, log link, and autoregressive correlation structure.

1349,747132,824 (38)719 (0.21)(ref)(ref)
2266,652134,590 (50)729 (0.27)1.31 (1.17‐1.45)1.07 (0.96‐1.18)
3251,042139,770 (56)922 (0.37)1.72 (1.56‐1.90)1.31 (1.19‐1.44)
4271,978169,189 (62)1071 (0.39)1.73 (1.57‐1.90)1.23 (1.12‐1.35)

DISCUSSION

In this analysis of a large cohort of hospitalized nonsurgical patients, we found that more than half of all patients received opioids, with 43% of those exposed receiving multiple opioids during their admission and 52% receiving opioids on the day of discharge. Considerable hospital variation in opioid use was evident, and this was not fully explained by patient characteristics. Severe opioid‐related adverse events occurred more frequently at hospitals with higher opioid‐prescribing rates, and the relative risk of a severe adverse event per patient prescribed opioids was also higher in these hospitals. To our knowledge, this is the first study to describe the scope of opioid utilization and the relationship between utilization and severe opioid‐related adverse events in a sample of nonsurgical patients in US acute‐care facilities.

Our use of naloxone charges and opioid‐specific ICD‐9‐CM coding to define an opioid‐related adverse event was intended to capture only the most severe opioid‐related adverse events. We chose to focus on these events in our analysis to maximize the specificity of our outcome definition and thereby minimize confounding in our observed associations. The rate of less‐severe opioid‐related adverse events, such as nausea, constipation, and pruritis, is likely much higher and not captured in our outcome definition. Prior analyses have found variable rates of opioid‐related adverse events of approximately 1.8% to 13.6% of exposed patients.[22, 23, 24] However, these analyses focused on surgical patients and included less‐severe events. To our knowledge, ours is the first analysis of severe opioid‐related adverse events in nonsurgical patients.

Our finding that severe opioid‐related adverse events increase as opioid prescribing increases is consistent with that which has been demonstrated in the community setting, where rates of opioid‐related adverse events and mortality are higher in communities with higher levels of opioid prescribing.[2, 8, 25] This finding is expected, as greater use of a class of medications with known side effects would be expected to result in a higher overall rate of adverse events. More concerning, however, is the fact that this relationship persists when focusing exclusively on opioid‐exposed patients. Among similar patients receiving opioids at different hospitals, those hospitalized in facilities with higher opioid‐prescribing rates have higher rates of severe opioid‐related adverse events. This suggests that hospitals that use opioids more frequently do not do so more safely. Rather, the increased overall prescribing rates are associated with heightened risk for a serious adverse event per patient exposed and may reflect unsafe prescribing practices.

Furthermore, our results demonstrate both regional and hospital variation in use of opioids not fully explained by patient characteristics, similar to that which has been demonstrated for other drugs and heathcare services.[26, 27, 28, 29, 30] The implications of these findings are limited by our lack of information on pain severity or prior outpatient treatment, and our resultant inability to evaluate the appropriateness of opioid use in this analysis. Additionally, although we controlled for a large number of patient and hospital characteristics, there could be other significant predictors of use not accounted for in our analysis. However, it seems unlikely that differential pain severity or patient characteristics between patients in different regions of the country could fully explain a 37% relative difference in prescribing between the lowest‐ and highest‐prescribing regions, after accounting for the 44 patient‐level variables in our models. Whereas variation in use unrelated to patient factors could represent inappropriate prescribing practices, it could also be a marker of uncertainty regarding what constitutes appropriate prescribing and high‐quality care in this realm. Although guidelines advocate for standard pain assessments and a step‐up approach to treatment,[31, 32, 33] the lack of objective measures of pain severity and lack of evidence‐based recommendations on the use of opioids for noncancer pain[34] will almost certainly lead to persistent variation in opioid prescribing despite guideline‐driven care.

Nonetheless, our findings suggest that opportunities exist to make opioid prescribing safer in hospitalized patients. Studies aimed at elucidating the source of regional and hospital variation are necessary. Additionally, efforts should focus on identifying patient and prescribing characteristics associated with heightened risk of opioid‐related adverse events. Prior studies have demonstrated that the risks of opioid medications increase with increasing age of the patient.[35, 36] Although opioid use in our cohort declined with age, 44% of admissions age 65 years had charges for opioid medications. Studies in outpatients have also demonstrated that the risks of opioid overdose and overdose‐related death increase with dose.[5, 7] One study demonstrated a 3.7‐fold increased risk of overdose at doses of 5099 mg/day in oral morphine equivalents, and an 8.9‐fold increased risk at doses of 100 mg/day, compared with doses of 20 mg/day.[7] The prevalence of high dose exposure observed in our cohort, coupled with the older age of hospitalized patients, suggests potential targets for promoting safer use in hospitalized patients through interventions such as computerized decision support and enhanced monitoring in those at highest risk.

Because medications after discharge were unavailable in our dataset, the percentage of patients given a prescription for opioid medication on discharge is unknown. However, given that opioids are often tapered rather than abruptly discontinued, our finding that 26% of hospitalized nonsurgical patients received opioids on the day of discharge suggests that a substantial proportion of patients may be discharged with a prescription for opioid medication. Given the possibility of coexistent outpatient opioid prescriptions, these findings draw attention to the importance of assuring development and streamlined accessibility of data from state prescription drug monitoring programs and suggest that increased attention should be paid to the role that inpatient opioid prescribing plays in the increased rates of chronic opioid use and overdose‐related deaths in the United States.

There are additional limitations to our analysis. First, although the database used for this analysis captures a large proportion of admissions to US acute‐care facilities and is similar in composition, it is possible that participating medical centers differ from nonparticipating medical centers in ways that could be associated with opioid prescribing. Additionally, although Premier performs extensive validation and correction processes to assure the quality of their data, there is still likely to be a small amount of random error in the database, which could particularly impact dosage calculations. The lack of preadmission medications in our database precluded identification of the proportion of patients newly started on opioid medications. Lastly, it is possible that the hospital prescribing‐rate quartile is associated with patient characteristics unaccounted for in our analysis, and, therefore, the possibility of residual confounding still exists.

In conclusion, the majority of hospitalized nonsurgical patients are exposed to opioid medications during the course of their hospitalizations, often at high doses. More than half of those exposed are still receiving these medications on the day of discharge. We found hospital and regional variation in opioid use that was not fully explained by patient characteristics, and higher levels of hospital use were associated with higher risk of severe opioid‐related adverse events in opioid‐exposed patients. Further research is necessary to investigate the appropriateness of opioid use in this patient population, the sources of variation in use, and the predictors of opioid‐related adverse events in hospitalized patients to allow development of interventions to make hospital use safer.

Disclosures

Disclosures: Dr. Herzig had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Dr. Herzig was funded by grant no. K23AG042459 from the National Institute on Aging. Dr. Marcantonio was funded by grant nos. P01AG031720, R01AG030618, R03AG028189, and K24AG035075 from the National Institute on Aging. The funding organization had no involvement in any aspect of the study, including design, conduct, and reporting of the study. None of the authors have any conflicts of interest to disclose.

Files
References
  1. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med. 2010;363(21):19811985.
  2. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf. 2006;15(9):618627.
  3. Pletcher MJ, Kertesz SG, Kohn MA, Gonzales R. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA. 2008;299(1):7078.
  4. Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA. 2000;283(13):17101714.
  5. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose‐related deaths. JAMA. 2011;305(13):13151321.
  6. Cerdá M, Ransome Y, Keyes KM, et al. Prescription opioid mortality trends in New York City, 1990–2006: examining the emergence of an epidemic. Drug Alcohol Depend. 2013;132(1‐2):5362.
  7. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):8592.
  8. Modarai F, Mack K, Hicks P, et al. Relationship of opioid prescription sales and overdoses, North Carolina. Drug Alcohol Depend. 2013;132(1‐2):8186.
  9. Tanne JH. Deaths from prescription opioids soar in New York. BMJ. 2013;346:f921.
  10. Haupt M, Cruz‐Jentoft A, Jeste D. Mortality in elderly dementia patients treated with risperidone. J Clin Psychopharmacol. 2006;26(6):566570.
  11. Pronovost P, Weast B, Schwarz M, et al. Medication reconciliation: a practical tool to reduce the risk of medication errors. J Crit Care. 2003;18(4):201205.
  12. Rozich JD, Haraden CR, Resar RK. Adverse drug event trigger tool: a practical methodology for measuring medication related harm. Qual Saf Health Care. 2003;12(3):194200.
  13. Nwulu U, Nirantharakumar K, Odesanya R, McDowell SE, Coleman JJ. Improvement in the detection of adverse drug events by the use of electronic health and prescription records: an evaluation of two trigger tools. Eur J Clin Pharmacol. 2013;69(2):255259.
  14. Elixhauser A, Owens P. Adverse Drug Events in U.S. Hospitals, 2004. Rockville, MD: Agency for Healthcare Research and Quality; April 2007. Statistical Brief 29.
  15. Lucado J, Paez K, Elixhauser A. Medication‐Related Adverse Outcomes in U.S. Hospitals and Emergency Departments, 2008. Rockville, MD: Agency for Healthcare Research and Quality; April 2011. Statistical Brief 109.
  16. US Centers for Medicare and Medicaid Services. Hospital‐Acquired Conditions (Present on Admission Indicator). Available at: http://www.cms.hhs.gov/HospitalAcqCond/. Accessed August 16, 2011. Updated September 20, 2012.
  17. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of morphine and opiates. J Intern Med. 2006;260(1):7687.
  18. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):827.
  19. Clinical Classifications Software, Healthcare Cost and Utilization Project (HCUP). Rockville, MD; Agency for Healthcare Research and Quality; December 2009.
  20. Gammaitoni AR, Fine P, Alvarez N, McPherson ML, Bergmark S. Clinical application of opioid equianalgesic data. Clin J Pain. 2003;19(5)286297.
  21. Svendsen K, Borchgrevink PC, Fredheim O, Hamunen K, Mellbye A, Dale O. Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses. Palliat Med. 2011;25(7):725732.
  22. Kessler ER, Shah M, Gruschkus SK, Raju A. Cost and quality implications of opioid‐based postsurgical pain control using administrative claims data from a large health system: opioid‐related adverse events and their impact on clinical and economic outcomes. Pharmacotherapy. 2013;33(4):383391.
  23. Oderda GM, Said Q, Evans RS, et al. Opioid‐related adverse drug events in surgical hospitalizations: impact on costs and length of stay. Ann Pharmacother. 2007;41(3):400406.
  24. Oderda GM, Evans RS, Lloyd J, et al. Cost of opioid‐related adverse drug events in surgical patients. J Pain Symptom Manage. 2003;25(3):276283.
  25. Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med. 2006;31(6):506511.
  26. O'Connor GT, Quinton HB, Traven ND, et al. Geographic variation in the treatment of acute myocardial infarction: the Cooperative Cardiovascular Project. JAMA. 1999;281(7):627633.
  27. Pilote L, Califf RM, Sapp S, et al; GUSTO‐1 Investigators. Regional variation across the United States in the management of acute myocardial infarction. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med. 1995;333(9):565572.
  28. Steinman MA, Landefeld CS, Gonzales R. Predictors of broad‐spectrum antibiotic prescribing for acute respiratory tract infections in adult primary care. JAMA. 2003;289(6):719725.
  29. Zhang Y, Baicker K, Newhouse JP. Geographic variation in Medicare drug spending. N Engl J Med. 2010;363(5):405409.
  30. Zhang Y, Steinman MA, Kaplan CM. Geographic variation in outpatient antibiotic prescribing among older adults. Arch Intern Med. 2012;172(19):14651471.
  31. Cantrill SV, Brown MD, Carlisle RJ, et al. Clinical policy: critical issues in the prescribing of opioids for adult patients in the emergency department. Ann Emerg Med. 2012;60(4):499525.
  32. The Joint Commission. Facts About Pain Management. Available at: http://www.jointcommission.org/pain_management/. Accessed July 23, 2012.
  33. The Joint Commission. Sentinel Event Alert: Safe Use of Opioids in Hospitals. Published August 8, 2012. Available at: http://www.jointcommission.org/assets/1/18/SEA_49_opioids_8_2_12_final.pdf. Accessed March 4, 2013.
  34. Chou R, Ballantyne JC, Fanciullo GJ, Fine PG, Miaskowski C. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10(2):147159.
  35. Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short‐term administration: effect of age, gender, and race. Clin Pharmacol Ther. 2003;74(2):102112.
  36. Taylor S, Kirton OC, Staff I, Kozol RA. Postoperative day one: a high‐risk period for respiratory events. Am J Surg. 2005;190(5):752756.
Article PDF
Issue
Journal of Hospital Medicine - 9(2)
Publications
Page Number
73-81
Sections
Files
Files
Article PDF
Article PDF

Recent reports have drawn attention to the high and increasing rates of opioid prescribing and overdose‐related deaths in the United States.[1, 2, 3, 4, 5, 6, 7, 8, 9] These studies have focused on community‐based and emergency department prescribing, leaving prescribing practices in the inpatient setting unexamined. Given that pain is a frequent complaint in hospitalized patients, and that the Joint Commission mandates assessing pain as a vital sign, hospitalization is potentially a time of heightened use of such medications and could significantly contribute to nosocomial complications and subsequent outpatient use.[10] Variation in prescribing practices, unrelated to patient characteristics, could be a marker of inappropriate prescribing practices and poor quality of care.

Using a large, nationally representative cohort of admissions from July 2009 to June 2010, we sought to determine patterns and predictors of opioid utilization in nonsurgical admissions to US medical centers, hospital variation in use, and the association between hospital‐level use and the risk of opioid‐related adverse events. We hypothesized that hospitals with higher rates of opioid use would have an increased risk of an opioid‐related adverse event per patient exposed.

METHODS

Setting and Patients

We conducted a retrospective cohort study using data from 286 US nonfederal acute‐care facilities contributing to the database maintained by Premier (Premier Healthcare Solutions, Inc., Charlotte, NC). This database, created to measure healthcare utilization and quality of care, is drawn from voluntarily participating hospitals and contains data on approximately 1 in every 4 discharges nationwide.[11] Participating hospitals are similar in geographic distribution and metropolitan (urban/rural) status to hospitals nationwide, although large, nonteaching hospitals are slightly overrepresented in Premier. The database contains patient demographics, International Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9‐CM) codes, hospital demographics, and a date‐stamped log of all charges during the course of each hospitalization, including diagnostic tests, therapeutic treatments, and medications with dose and route of administration. The study was approved by the institutional review board at Beth Israel Deaconess Medical Center and granted a waiver of informed consent.

We studied a cohort of all adult nonsurgical admissions to participating hospitals from July 1, 2009, through June 30, 2010. We chose to study nonsurgical admissions, as patients undergoing surgical procedures have a clear indication for, and almost always receive, opioid pain medications. We defined a nonsurgical admission as an admission in which there were no charges for operating‐room procedures (including labor and delivery) and the attending of record was not a surgeon. We excluded admissions with unknown gender, since this is a key demographic variable, and admissions with a length of stay greater than 365 days, as these admissions are not representative of the typical admission to an acute‐care hospital. At the hospital level, we excluded hospitals contributing <100 admissions owing to resultant lack of precision in corresponding hospital prescribing rates, and hospitals that did not prescribe the full range of opioid medications (these hospitals had charges for codeine only), as these facilities seemed likely to have unusual limitations on prescribing or incomplete data capture.

Opioid Exposure

We defined opioid exposure as presence of 1 charge for an opioid medication during the admission. Opioid medications included morphine, hydrocodone, hydromorphone, oxycodone, fentanyl, meperidine, methadone, codeine, tramadol, buprenorphine, levorphanol, oxymorphone, pentazocine, propoxyphene, tapentadol, butorphanol, dezocine, and nalbuphine. We grouped the last 9 into an other category owing to infrequent use and/or differing characteristics from the main opioid drug types, such as synthetic, semisynthetic, and partial agonist qualities.

Severe Opioid‐Related Adverse Events

We defined severe opioid‐related adverse events as either naloxone exposure or an opioid‐related adverse drug event diagnosis code. Naloxone use in an adult patient exposed to opioids is one of the Institute for Healthcare Improvement's Trigger Tools for identifying adverse drug events[12] and previously has been demonstrated to have high positive predictive value for a confirmed adverse drug event.[13] We defined naloxone exposure as presence of 1 charge for naloxone. We excluded charges on hospital day 1 to focus on nosocomial events. We defined opioid‐related adverse drug events using ICD‐9‐CM diagnosis codes for poisoning by opioids (overdose, wrong substance given, or taken in error; ICD‐9‐CM 965.02, 965.09, E850.1, E850.2) and drugs causing adverse effects in therapeutic use (ICD‐9‐CM E935.1, E935.2), as specified in prior analyses by the Agency for Healthcare Research and Quality (AHRQ).[14, 15] To avoid capturing adverse events associated with outpatient use, we required the ICD‐9‐CM code to be qualified as not present on admission using the present on admission indicator required by the Centers for Medicare and Medicaid Services for all discharge diagnosis codes since 2008.[16]

Covariates of Interest

We were interested in the relationship between both patient and hospital characteristics and opioid exposure. Patient characteristics of interest included (1) demographic variables, such as age, sex, race (self‐reported by patients at the time of admission), marital status, and payer; (2) whether or not the patient spent any time in the intensive care unit (ICU); (3) comorbidities, identified via ICD‐9‐CM secondary diagnosis codes and diagnosis‐related groups using Healthcare Cost and Utilization Project Comorbidity Software, version 3.7, based on the work of Elixhauser et al[17, 18]; (4) primary ICD‐9‐CM discharge diagnosis groupings, selected based on hypothesized associations with receipt of opioids, and based on the Clinical Classifications Software (CCS)a diagnosis and procedure categorization scheme maintained by the AHRQ, and defined in the Appendix[19]; (5) and nonoperating‐room‐based procedures potentially necessitating opioids during the admission, selected from the 50 most common ICD‐9‐CM procedure codes in our cohort and grouped as cardiovascular procedures (catheterization and insertion of vascular stents), gastrointestinal procedures (upper and lower endoscopy), and mechanical ventilation, further defined in the Appendix. Hospital characteristics of interest included number of beds, population served (urban vs rural), teaching status, and US census region (Northeast, Midwest, South, West).

Statistical Analysis

We calculated the percent of admissions with exposure to any opioid and the percent exposed to each opioid, along with the total number of different opioid medications used during each admission. We also calculated the percent of admissions with parenteral administration and the percent of admissions with oral administration, among those exposed to the individual categories, and in aggregate. Because medications after discharge were unavailable in Premier's dataset, we report the percent of patients with a charge for opioids on the day of discharge.

We determined the daily dose of an opioid by taking the sum of the doses for that opioid charged on a given day. The average daily dose of an opioid was determined by taking the sum of the daily doses and dividing by the number of days on which 1 dose was charged. To facilitate comparison, all opioids, with the exception of those for which standard equivalences are unavailable (tramadol, other opioid category, oral fentanyl, epidural route for all), were converted to oral morphine equivalents using a standard equivalence conversion table.[20, 21] We excluded from our dosage calculations those charges for which standard morphine equivalence was unavailable, or for which dosage was missing. We also excluded from our dosage calculations any dose that was >3 standard deviations (SD) above the mean dose for that opioid, as such extreme values seemed physiologically implausible and more likely to be a data entry error that could lead to significant overestimation of the mean for that opioid.

All multivariable models used a generalized estimating equation (GEE) via the genmod procedure in SAS, with a Poisson distribution error term and a log link, controlling for repeated patient admissions with an autoregressive correlation structure.

To identify independent predictors of opioid receipt, we used a GEE model of opioid receipt where all patient and hospital characteristics listed in Table 1 were included as independent variables.

Patient and Hospital Characteristics
Patient characteristics, N=1,139,419N%
  • NOTE: Abbreviations: AIDS, acquired immune deficiency syndrome; CHF, congestive heart failure; DM, diabetes mellitus; GI, gastrointestinal; ICU, intensive care unit; PVD, peripheral vascular disease; RA, rheumatoid arthritis; US, United States.

  • Patient characteristics presented for each admission do not take into account multiple admissions of the same patient.

  • Pain‐related diagnoses include abdominal pain, headache, nonspecific chest pain, pancreatic disorders, musculoskeletal back problems, and calculus of urinary tract.

Age group, y  
182437,4643
253466,5416
3544102,7019
4554174,83015
5564192,57017
6574196,40717
75+368,90632
Sex  
Male527,06246
Female612,35754
Race  
White711,99362
Black176,99316
Hispanic54,4065
Other196,02717
Marital status  
Married427,64838
Single586,34351
Unknown/other125,42811
Primary insurance  
Private/commercial269,72524
Medicare traditional502,30144
Medicare managed care126,34411
Medicaid125,02511
Self‐pay/other116,02410
ICU care  
No1,023,02790
Yes116,39210
Comorbidities  
AIDS57241
Alcohol abuse79,6337
Deficiency anemias213,43719
RA/collagen vascular disease35,2103
Chronic blood‐loss anemia10,8601
CHF190,08517
Chronic pulmonary disease285,95425
Coagulopathy48,5134
Depression145,55313
DM without chronic complications270,08724
DM with chronic complications70,7326
Drug abuse66,8866
Hypertension696,29961
Hypothyroidism146,13613
Liver disease38,1303
Lymphoma14,0321
Fluid and electrolyte disorders326,57629
Metastatic cancer33,4353
Other neurological disorders124,19511
Obesity118,91510
Paralysis38,5843
PVD77,3347
Psychoses101,8569
Pulmonary circulation disease52,1065
Renal failure175,39815
Solid tumor without metastasis29,5943
Peptic ulcer disease excluding bleeding5360
Valvular disease86,6168
Weight loss45,1324
Primary discharge diagnoses  
Cancer19,1682
Musculoskeletal injuries16,7981
Pain‐related diagnosesb101,5339
Alcohol‐related disorders16,7771
Substance‐related disorders13,6971
Psychiatric disorders41,1534
Mood disorders28,7613
Schizophrenia and other psychotic disorders12,3921
Procedures  
Cardiovascular procedures59,9015
GI procedures31,2243
Mechanical ventilation78531
Hospital characteristics, N=286  
Number of beds  
<20010336
2013006322
3015008128
>5003914
Population served  
Urban22579
Rural6121
Teaching status  
Nonteaching20772
Teaching7928
US Census region  
Northeast4716
Midwest6322
South11540
West6121

To assess hospital variation in opioid prescribing after adjusting for patient characteristics, we used a GEE model of opioid receipt, controlling for all patient characteristics listed in Table 1. We then took the mean of the predicted probabilities of opioid receipt for the patients within each hospital in our cohort to derive the hospital prescribing rate adjusted for patient characteristics. We report the mean, SD, and range of the prescribing rates for the hospitals in our cohort before and after adjustment for patient characteristics.

To assess whether patients admitted to hospitals with higher rates of opioid prescribing have higher relative risk of severe opioid‐related adverse events, we stratified hospitals into opioid‐prescribing rate quartiles and compared the rates of opioid‐related adverse eventsboth overall and among opioid exposedbetween quartiles. To adjust for patient characteristics, we used a GEE model in which severe opioid‐related adverse event (yes/no) was the dependent variable and hospital‐prescribing rate quartile and all patient characteristics in Table 1 were independent variables. We also performed a sensitivity analysis in which we assessed the association between hospital prescribing‐rate quartile and the individual components of our composite outcome. Our results were qualitatively unchanged using this approach, and only the results of our main analysis are presented.

All analyses were carried out using SAS software, version 9.2 (SAS Institute Inc., Cary, NC).

RESULTS

Patient Admission Characteristics

There were 3,190,934 adult admissions to 300 acute‐care hospitals during our study period. After excluding admissions with a length of stay >365 days (n=25), missing patient sex (n=17), and charges for operating‐room procedures or a surgical attending of record (n=2,018,553), 1,172,339 admissions were available for analysis. There were 12 hospitals with incomplete opioid‐prescribing data (n=32,794) and 2 hospitals that contributed <100 admissions each (n=126), leaving 1,139,419 admissions in 286 hospitals in our analytic cohort. The median age of the cohort was 64 years (interquartile range, 4979 years), and 527,062 (46%) were men. Table 1 shows the characteristics of the admissions in the cohort.

Rate, Route, and Dose of Opioid Exposures

Overall, there were 576,373 (51%) admissions with charges for opioid medications. Among those exposed, 244,760 (43%) had charges for multiple opioids during the admission; 172,090 (30%) had charges for 2 different opioids; and 72,670 (13%) had charges for 3 different opioids. Table 2 shows the percent exposed to each opioid, the percent of exposed with parenteral and oral routes of administration, and the mean daily dose received in oral morphine equivalents.

Rate of Exposure, Route of Administration, and Average Dose of Opioids Received, Overall and by Opioid (N=1,139,419)
 ExposedParenteral AdministrationOral AdministrationDose Received, in Oral Morphine Equivalents
 N%aN%bN%bMeanSDc
  • NOTE: Abbreviations: SD, standard deviation.

  • Percentages exposed to different opioids add up to more than total receiving any opioid since patients may be exposed to >1 opioid during their hospitalization.

  • Denominator is the number exposed. Percentages may add up to100% owing to missing route information or receipt of both parenteral and oral routes, respectively.

  • On days on which opioids were received. Charges for tramadol, other category opioids, oral fentanyl (0.7% of fentanyl charges), and epidural‐route opioids (3.5% of fentanyl charges, 0.1% of morphine charges, and 0.1% of hydromorphone charges) were not included in dosage calculations due to lack of standard conversion factor to morphine equivalents. Charges with missing dose were also excluded (2% of total remaining opioid charges). Includes the following opioids: buprenorphine, levorphanol, oxymorphone, pentazocine, propoxyphene, tapentadol, butorphanol, dezocine, and nalbuphine.

All opioids576,37351378,77166371,7966568185
Morphine224,81120209,0409321,6451040121
Hydrocodone162,5581400160,941991412
Hydromorphone146,23613137,9369416,05211113274
Oxycodone126,7331100125,033992637
Fentanyl105,0529103,1139864116475
Tramadol35,57030035,570100  
Meperidine24,850224,3989851523634
Methadone15,3021370214,78197337384
Codeine22,8182178122,18397915
Other45,469458211339,61887  

Among the medications/routes for which conversion to morphine equivalents was possible, dosage was missing in 39,728 out of 2,294,673 opioid charges (2%). The average daily dose received in oral morphine equivalents was 68 mg. A total dose of 50 mg per day was received in 39% of exposed, and a total dose of 100 mg per day was received in 23% of exposed. Among those exposed, 52% (26% of overall admissions) had charges for opioids on the day of discharge.

Rates of Opioid Use by Patient and Hospital Characteristics

Table 3 reports the association between admission characteristics and opioid use. Use was highest in patients between the ages of 25 and 54 years. Although use declined with age, 44% of admissions age 65 years had charges for opioid medication. After adjustment for patient demographics, comorbidities, and hospital characteristics, opioid use was more common in females than males, those age 2554 years compared with those older and younger, those of Caucasian race compared with non‐Caucasian race, and those with Medicare or Medicaid primary insurance. Among the primary discharge diagnoses, patients with musculoskeletal injuries, various specific and nonspecific pain‐related diagnoses, and cancer were significantly more likely to receive opioids than patients without these diagnoses, whereas patients with alcohol‐related disorders and psychiatric disorders were significantly less likely to receive opioids than patients without these diagnoses. Patients admitted to hospitals in the Midwest, South, and West were significantly more likely to receive opioid medications than patients in the Northeast.

Association Between Admission Characteristics and Opioid Use (N=1,139,419)
 Exposed, N=576,373Unexposed, N=563,046% ExposedAdjusted RRa95% CI
  • NOTE: Abbreviations: AIDS, acquired immune deficiency syndrome; CHF, congestive heart failure; CI, confidence interval; DM, diabetes mellitus; GEE, generalized estimating equation; GI, gastrointestinal; ICU, intensive care unit; PVD, peripheral vascular disease; RA, rheumatoid arthritis; ref, reference; RR, relative risk; US, United States.

  • Multivariable GEE model used to account for multiple admissions of the same patient, with simultaneous control for all variables listed in this table.

  • For comorbidities, primary discharge diagnoses, and procedures, the reference group is absence of that condition or procedure.

  • Pain‐related diagnoses include abdominal pain, headache, nonspecific chest pain, pancreatic disorders, musculoskeletal back problems, and calculus of urinary tract.

Patient characteristics     
Age group, y     
182417,36020,10446(ref) 
253437,79328,748571.171.16‐1.19
354460,71241,989591.161.15‐1.17
4554103,79871,032591.111.09‐1.12
5564108,25684,314561.000.98‐1.01
657498,11098,297500.840.83‐0.85
75+150,344218,562410.710.70‐0.72
Sex     
Male255,315271,74748(ref) 
Female321,058291,299521.111.10‐1.11
Race     
White365,107346,88651(ref) 
Black92,01384,980520.930.92‐0.93
Hispanic27,59226,814510.940.93‐0.94
Other91,661104,366470.930.92‐0.93
Marital status     
Married222,912204,73652(ref) 
Single297,742288,601511.000.99‐1.01
Unknown/other55,71969,709440.940.93‐0.95
Primary insurance     
Private/commercial143,954125,77153(ref) 
Medicare traditional236,114266,187471.101.09‐1.10
Medicare managed care59,10467,240471.111.11‐1.12
Medicaid73,58351,442591.131.12‐1.13
Self‐pay/other63,61852,406551.031.02‐1.04
ICU care     
No510,654512,37350(ref) 
Yes65,71950,673561.021.01‐1.03
Comorbiditiesb     
AIDS36552069641.091.07‐1.12
Alcohol abuse35,11244,521440.920.91‐0.93
Deficiency anemias115,84297,595541.081.08‐1.09
RA/collagen vascular disease22,51912,691641.221.21‐1.23
Chronic blood‐loss anemia64444416591.041.02‐1.05
CHF88,895101,190470.990.98‐0.99
Chronic pulmonary disease153,667132,287541.081.08‐1.08
Coagulopathy25,80222,711531.031.02‐1.04
Depression83,05162,502571.081.08‐1.09
DM without chronic complications136,184133,903500.990.99‐0.99
DM with chronic complications38,69632,036551.041.03‐1.05
Drug abuse37,20229,684561.141.13‐1.15
Hypertension344,718351,581500.980.97‐0.98
Hypothyroidism70,78675,350480.990.99‐0.99
Liver disease24,06714,063631.151.14‐1.16
Lymphoma77276305551.161.14‐1.17
Fluid and electrolyte disorders168,814157,762521.041.03‐1.04
Metastatic cancer23,9209515721.401.39‐1.42
Other neurological disorders51,09173,104410.870.86‐0.87
Obesity69,58449,331591.051.04‐1.05
Paralysis17,49721,087450.970.96‐0.98
PVD42,17635,158551.111.11‐1.12
Psychoses38,63863,218380.910.90‐0.92
Pulmonary circulation disease26,65625,450511.051.04‐1.06
Renal failure86,56588,833491.011.01‐1.02
Solid tumor without metastasis16,25813,336551.141.13‐1.15
Peptic ulcer disease excluding bleeding376160701.121.07‐1.18
Valvular disease38,39648,220440.930.92‐0.94
Weight loss25,72419,408571.091.08‐1.10
Primary discharge diagnosesb     
Cancer13,9865182731.201.19‐1.21
Musculoskeletal injuries14,6382160872.022.002.04
Pain‐related diagnosesc64,65636,877641.201.20‐1.21
Alcohol‐related disorders342513,352200.460.44‐0.47
Substance‐related disorders86805017631.031.01‐1.04
Psychiatric disorders725333,900180.370.36‐0.38
Mood disorders594322,81821  
Schizophrenia and other psychotic disorders131011,08211  
Proceduresb     
Cardiovascular procedures50,9978904851.801.79‐1.81
GI procedures27,2064018871.701.69‐1.71
Mechanical ventilation53412512681.371.34‐1.39
Hospital characteristics     
Number of beds     
<200100,90088,43953(ref) 
201300104,21399,995510.950.95‐0.96
301500215,340209,104510.940.94‐0.95
>500155,920165,508490.960.95‐0.96
Population served     
Urban511,727506,80350(ref) 
Rural64,64656,243530.980.97‐0.99
Teaching status     
Nonteaching366,623343,58152(ref) 
Teaching209,750219,465491.000.99‐1.01
US Census region     
Northeast99,377149,44640(ref) 
Midwest123,194120,322511.26(1.25‐1.27)
South251,624213,029541.33(1.33‐1.34)
West102,17880,249561.37(1.36‐1.38)

Variation in Opioid Prescribing

Figure 1 shows the histograms of hospital opioid prescribing rate for the 286 hospitals in our cohort (A) before and (B) after adjustment for patient characteristics. The observed rates ranged from 5% in the lowest‐prescribing hospital to 72% in the highest‐prescribing hospital, with a mean (SD) of 51% (10%). After adjusting for patient characteristics, the adjusted opioid‐prescribing rates ranged from 33% to 64%, with a mean (SD) of 50% (4%).

Figure 1
Histograms of hospital opioid prescribing rate (A) before and (B) after adjustment for patient characteristics.

Severe Opioid‐Related Adverse Events

Among admissions with opioid exposure (n=576,373), naloxone use occurred in 2345 (0.41%) and opioid‐related adverse drug events in 1174 (0.20%), for a total of 3441 (0.60%) severe opioid‐related adverse events (some patients experienced both). Table 4 reports the opioid exposure and severe opioid‐related adverse‐event rates within hospital opioid‐prescribing rate quartiles, along with the adjusted association between the hospital opioid‐prescribing rate quartile and severe opioid‐related adverse events. After adjusting for patient characteristics, the relative risk of a severe opioid‐related adverse event was significantly greater in hospitals with higher opioid‐prescribing rates, both overall and among opioid exposed.

Association Between Hospital Opioid‐Prescribing Rate Quartile and Risk of an Opioid‐Related Adverse Event
QuartileNo. of PatientsOpioid Exposed, n (%)Opioid‐Related Adverse Events, n (%)Adjusted RR in All Patients, RR (95% CI), N=1,139,419aAdjusted RR in Opioid Exposed, RR (95% CI), N=576,373a
  • NOTE: Abbreviations: CI, confidence interval; GEE, generalized estimating equation; ref, reference; ref, reference; RR, relative risk.

  • Adjusted for repeated admissions and patient characteristics presented in Table 1 using a multivariable GEE model with a Poisson error term distribution, log link, and autoregressive correlation structure.

1349,747132,824 (38)719 (0.21)(ref)(ref)
2266,652134,590 (50)729 (0.27)1.31 (1.17‐1.45)1.07 (0.96‐1.18)
3251,042139,770 (56)922 (0.37)1.72 (1.56‐1.90)1.31 (1.19‐1.44)
4271,978169,189 (62)1071 (0.39)1.73 (1.57‐1.90)1.23 (1.12‐1.35)

DISCUSSION

In this analysis of a large cohort of hospitalized nonsurgical patients, we found that more than half of all patients received opioids, with 43% of those exposed receiving multiple opioids during their admission and 52% receiving opioids on the day of discharge. Considerable hospital variation in opioid use was evident, and this was not fully explained by patient characteristics. Severe opioid‐related adverse events occurred more frequently at hospitals with higher opioid‐prescribing rates, and the relative risk of a severe adverse event per patient prescribed opioids was also higher in these hospitals. To our knowledge, this is the first study to describe the scope of opioid utilization and the relationship between utilization and severe opioid‐related adverse events in a sample of nonsurgical patients in US acute‐care facilities.

Our use of naloxone charges and opioid‐specific ICD‐9‐CM coding to define an opioid‐related adverse event was intended to capture only the most severe opioid‐related adverse events. We chose to focus on these events in our analysis to maximize the specificity of our outcome definition and thereby minimize confounding in our observed associations. The rate of less‐severe opioid‐related adverse events, such as nausea, constipation, and pruritis, is likely much higher and not captured in our outcome definition. Prior analyses have found variable rates of opioid‐related adverse events of approximately 1.8% to 13.6% of exposed patients.[22, 23, 24] However, these analyses focused on surgical patients and included less‐severe events. To our knowledge, ours is the first analysis of severe opioid‐related adverse events in nonsurgical patients.

Our finding that severe opioid‐related adverse events increase as opioid prescribing increases is consistent with that which has been demonstrated in the community setting, where rates of opioid‐related adverse events and mortality are higher in communities with higher levels of opioid prescribing.[2, 8, 25] This finding is expected, as greater use of a class of medications with known side effects would be expected to result in a higher overall rate of adverse events. More concerning, however, is the fact that this relationship persists when focusing exclusively on opioid‐exposed patients. Among similar patients receiving opioids at different hospitals, those hospitalized in facilities with higher opioid‐prescribing rates have higher rates of severe opioid‐related adverse events. This suggests that hospitals that use opioids more frequently do not do so more safely. Rather, the increased overall prescribing rates are associated with heightened risk for a serious adverse event per patient exposed and may reflect unsafe prescribing practices.

Furthermore, our results demonstrate both regional and hospital variation in use of opioids not fully explained by patient characteristics, similar to that which has been demonstrated for other drugs and heathcare services.[26, 27, 28, 29, 30] The implications of these findings are limited by our lack of information on pain severity or prior outpatient treatment, and our resultant inability to evaluate the appropriateness of opioid use in this analysis. Additionally, although we controlled for a large number of patient and hospital characteristics, there could be other significant predictors of use not accounted for in our analysis. However, it seems unlikely that differential pain severity or patient characteristics between patients in different regions of the country could fully explain a 37% relative difference in prescribing between the lowest‐ and highest‐prescribing regions, after accounting for the 44 patient‐level variables in our models. Whereas variation in use unrelated to patient factors could represent inappropriate prescribing practices, it could also be a marker of uncertainty regarding what constitutes appropriate prescribing and high‐quality care in this realm. Although guidelines advocate for standard pain assessments and a step‐up approach to treatment,[31, 32, 33] the lack of objective measures of pain severity and lack of evidence‐based recommendations on the use of opioids for noncancer pain[34] will almost certainly lead to persistent variation in opioid prescribing despite guideline‐driven care.

Nonetheless, our findings suggest that opportunities exist to make opioid prescribing safer in hospitalized patients. Studies aimed at elucidating the source of regional and hospital variation are necessary. Additionally, efforts should focus on identifying patient and prescribing characteristics associated with heightened risk of opioid‐related adverse events. Prior studies have demonstrated that the risks of opioid medications increase with increasing age of the patient.[35, 36] Although opioid use in our cohort declined with age, 44% of admissions age 65 years had charges for opioid medications. Studies in outpatients have also demonstrated that the risks of opioid overdose and overdose‐related death increase with dose.[5, 7] One study demonstrated a 3.7‐fold increased risk of overdose at doses of 5099 mg/day in oral morphine equivalents, and an 8.9‐fold increased risk at doses of 100 mg/day, compared with doses of 20 mg/day.[7] The prevalence of high dose exposure observed in our cohort, coupled with the older age of hospitalized patients, suggests potential targets for promoting safer use in hospitalized patients through interventions such as computerized decision support and enhanced monitoring in those at highest risk.

Because medications after discharge were unavailable in our dataset, the percentage of patients given a prescription for opioid medication on discharge is unknown. However, given that opioids are often tapered rather than abruptly discontinued, our finding that 26% of hospitalized nonsurgical patients received opioids on the day of discharge suggests that a substantial proportion of patients may be discharged with a prescription for opioid medication. Given the possibility of coexistent outpatient opioid prescriptions, these findings draw attention to the importance of assuring development and streamlined accessibility of data from state prescription drug monitoring programs and suggest that increased attention should be paid to the role that inpatient opioid prescribing plays in the increased rates of chronic opioid use and overdose‐related deaths in the United States.

There are additional limitations to our analysis. First, although the database used for this analysis captures a large proportion of admissions to US acute‐care facilities and is similar in composition, it is possible that participating medical centers differ from nonparticipating medical centers in ways that could be associated with opioid prescribing. Additionally, although Premier performs extensive validation and correction processes to assure the quality of their data, there is still likely to be a small amount of random error in the database, which could particularly impact dosage calculations. The lack of preadmission medications in our database precluded identification of the proportion of patients newly started on opioid medications. Lastly, it is possible that the hospital prescribing‐rate quartile is associated with patient characteristics unaccounted for in our analysis, and, therefore, the possibility of residual confounding still exists.

In conclusion, the majority of hospitalized nonsurgical patients are exposed to opioid medications during the course of their hospitalizations, often at high doses. More than half of those exposed are still receiving these medications on the day of discharge. We found hospital and regional variation in opioid use that was not fully explained by patient characteristics, and higher levels of hospital use were associated with higher risk of severe opioid‐related adverse events in opioid‐exposed patients. Further research is necessary to investigate the appropriateness of opioid use in this patient population, the sources of variation in use, and the predictors of opioid‐related adverse events in hospitalized patients to allow development of interventions to make hospital use safer.

Disclosures

Disclosures: Dr. Herzig had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Dr. Herzig was funded by grant no. K23AG042459 from the National Institute on Aging. Dr. Marcantonio was funded by grant nos. P01AG031720, R01AG030618, R03AG028189, and K24AG035075 from the National Institute on Aging. The funding organization had no involvement in any aspect of the study, including design, conduct, and reporting of the study. None of the authors have any conflicts of interest to disclose.

Recent reports have drawn attention to the high and increasing rates of opioid prescribing and overdose‐related deaths in the United States.[1, 2, 3, 4, 5, 6, 7, 8, 9] These studies have focused on community‐based and emergency department prescribing, leaving prescribing practices in the inpatient setting unexamined. Given that pain is a frequent complaint in hospitalized patients, and that the Joint Commission mandates assessing pain as a vital sign, hospitalization is potentially a time of heightened use of such medications and could significantly contribute to nosocomial complications and subsequent outpatient use.[10] Variation in prescribing practices, unrelated to patient characteristics, could be a marker of inappropriate prescribing practices and poor quality of care.

Using a large, nationally representative cohort of admissions from July 2009 to June 2010, we sought to determine patterns and predictors of opioid utilization in nonsurgical admissions to US medical centers, hospital variation in use, and the association between hospital‐level use and the risk of opioid‐related adverse events. We hypothesized that hospitals with higher rates of opioid use would have an increased risk of an opioid‐related adverse event per patient exposed.

METHODS

Setting and Patients

We conducted a retrospective cohort study using data from 286 US nonfederal acute‐care facilities contributing to the database maintained by Premier (Premier Healthcare Solutions, Inc., Charlotte, NC). This database, created to measure healthcare utilization and quality of care, is drawn from voluntarily participating hospitals and contains data on approximately 1 in every 4 discharges nationwide.[11] Participating hospitals are similar in geographic distribution and metropolitan (urban/rural) status to hospitals nationwide, although large, nonteaching hospitals are slightly overrepresented in Premier. The database contains patient demographics, International Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9‐CM) codes, hospital demographics, and a date‐stamped log of all charges during the course of each hospitalization, including diagnostic tests, therapeutic treatments, and medications with dose and route of administration. The study was approved by the institutional review board at Beth Israel Deaconess Medical Center and granted a waiver of informed consent.

We studied a cohort of all adult nonsurgical admissions to participating hospitals from July 1, 2009, through June 30, 2010. We chose to study nonsurgical admissions, as patients undergoing surgical procedures have a clear indication for, and almost always receive, opioid pain medications. We defined a nonsurgical admission as an admission in which there were no charges for operating‐room procedures (including labor and delivery) and the attending of record was not a surgeon. We excluded admissions with unknown gender, since this is a key demographic variable, and admissions with a length of stay greater than 365 days, as these admissions are not representative of the typical admission to an acute‐care hospital. At the hospital level, we excluded hospitals contributing <100 admissions owing to resultant lack of precision in corresponding hospital prescribing rates, and hospitals that did not prescribe the full range of opioid medications (these hospitals had charges for codeine only), as these facilities seemed likely to have unusual limitations on prescribing or incomplete data capture.

Opioid Exposure

We defined opioid exposure as presence of 1 charge for an opioid medication during the admission. Opioid medications included morphine, hydrocodone, hydromorphone, oxycodone, fentanyl, meperidine, methadone, codeine, tramadol, buprenorphine, levorphanol, oxymorphone, pentazocine, propoxyphene, tapentadol, butorphanol, dezocine, and nalbuphine. We grouped the last 9 into an other category owing to infrequent use and/or differing characteristics from the main opioid drug types, such as synthetic, semisynthetic, and partial agonist qualities.

Severe Opioid‐Related Adverse Events

We defined severe opioid‐related adverse events as either naloxone exposure or an opioid‐related adverse drug event diagnosis code. Naloxone use in an adult patient exposed to opioids is one of the Institute for Healthcare Improvement's Trigger Tools for identifying adverse drug events[12] and previously has been demonstrated to have high positive predictive value for a confirmed adverse drug event.[13] We defined naloxone exposure as presence of 1 charge for naloxone. We excluded charges on hospital day 1 to focus on nosocomial events. We defined opioid‐related adverse drug events using ICD‐9‐CM diagnosis codes for poisoning by opioids (overdose, wrong substance given, or taken in error; ICD‐9‐CM 965.02, 965.09, E850.1, E850.2) and drugs causing adverse effects in therapeutic use (ICD‐9‐CM E935.1, E935.2), as specified in prior analyses by the Agency for Healthcare Research and Quality (AHRQ).[14, 15] To avoid capturing adverse events associated with outpatient use, we required the ICD‐9‐CM code to be qualified as not present on admission using the present on admission indicator required by the Centers for Medicare and Medicaid Services for all discharge diagnosis codes since 2008.[16]

Covariates of Interest

We were interested in the relationship between both patient and hospital characteristics and opioid exposure. Patient characteristics of interest included (1) demographic variables, such as age, sex, race (self‐reported by patients at the time of admission), marital status, and payer; (2) whether or not the patient spent any time in the intensive care unit (ICU); (3) comorbidities, identified via ICD‐9‐CM secondary diagnosis codes and diagnosis‐related groups using Healthcare Cost and Utilization Project Comorbidity Software, version 3.7, based on the work of Elixhauser et al[17, 18]; (4) primary ICD‐9‐CM discharge diagnosis groupings, selected based on hypothesized associations with receipt of opioids, and based on the Clinical Classifications Software (CCS)a diagnosis and procedure categorization scheme maintained by the AHRQ, and defined in the Appendix[19]; (5) and nonoperating‐room‐based procedures potentially necessitating opioids during the admission, selected from the 50 most common ICD‐9‐CM procedure codes in our cohort and grouped as cardiovascular procedures (catheterization and insertion of vascular stents), gastrointestinal procedures (upper and lower endoscopy), and mechanical ventilation, further defined in the Appendix. Hospital characteristics of interest included number of beds, population served (urban vs rural), teaching status, and US census region (Northeast, Midwest, South, West).

Statistical Analysis

We calculated the percent of admissions with exposure to any opioid and the percent exposed to each opioid, along with the total number of different opioid medications used during each admission. We also calculated the percent of admissions with parenteral administration and the percent of admissions with oral administration, among those exposed to the individual categories, and in aggregate. Because medications after discharge were unavailable in Premier's dataset, we report the percent of patients with a charge for opioids on the day of discharge.

We determined the daily dose of an opioid by taking the sum of the doses for that opioid charged on a given day. The average daily dose of an opioid was determined by taking the sum of the daily doses and dividing by the number of days on which 1 dose was charged. To facilitate comparison, all opioids, with the exception of those for which standard equivalences are unavailable (tramadol, other opioid category, oral fentanyl, epidural route for all), were converted to oral morphine equivalents using a standard equivalence conversion table.[20, 21] We excluded from our dosage calculations those charges for which standard morphine equivalence was unavailable, or for which dosage was missing. We also excluded from our dosage calculations any dose that was >3 standard deviations (SD) above the mean dose for that opioid, as such extreme values seemed physiologically implausible and more likely to be a data entry error that could lead to significant overestimation of the mean for that opioid.

All multivariable models used a generalized estimating equation (GEE) via the genmod procedure in SAS, with a Poisson distribution error term and a log link, controlling for repeated patient admissions with an autoregressive correlation structure.

To identify independent predictors of opioid receipt, we used a GEE model of opioid receipt where all patient and hospital characteristics listed in Table 1 were included as independent variables.

Patient and Hospital Characteristics
Patient characteristics, N=1,139,419N%
  • NOTE: Abbreviations: AIDS, acquired immune deficiency syndrome; CHF, congestive heart failure; DM, diabetes mellitus; GI, gastrointestinal; ICU, intensive care unit; PVD, peripheral vascular disease; RA, rheumatoid arthritis; US, United States.

  • Patient characteristics presented for each admission do not take into account multiple admissions of the same patient.

  • Pain‐related diagnoses include abdominal pain, headache, nonspecific chest pain, pancreatic disorders, musculoskeletal back problems, and calculus of urinary tract.

Age group, y  
182437,4643
253466,5416
3544102,7019
4554174,83015
5564192,57017
6574196,40717
75+368,90632
Sex  
Male527,06246
Female612,35754
Race  
White711,99362
Black176,99316
Hispanic54,4065
Other196,02717
Marital status  
Married427,64838
Single586,34351
Unknown/other125,42811
Primary insurance  
Private/commercial269,72524
Medicare traditional502,30144
Medicare managed care126,34411
Medicaid125,02511
Self‐pay/other116,02410
ICU care  
No1,023,02790
Yes116,39210
Comorbidities  
AIDS57241
Alcohol abuse79,6337
Deficiency anemias213,43719
RA/collagen vascular disease35,2103
Chronic blood‐loss anemia10,8601
CHF190,08517
Chronic pulmonary disease285,95425
Coagulopathy48,5134
Depression145,55313
DM without chronic complications270,08724
DM with chronic complications70,7326
Drug abuse66,8866
Hypertension696,29961
Hypothyroidism146,13613
Liver disease38,1303
Lymphoma14,0321
Fluid and electrolyte disorders326,57629
Metastatic cancer33,4353
Other neurological disorders124,19511
Obesity118,91510
Paralysis38,5843
PVD77,3347
Psychoses101,8569
Pulmonary circulation disease52,1065
Renal failure175,39815
Solid tumor without metastasis29,5943
Peptic ulcer disease excluding bleeding5360
Valvular disease86,6168
Weight loss45,1324
Primary discharge diagnoses  
Cancer19,1682
Musculoskeletal injuries16,7981
Pain‐related diagnosesb101,5339
Alcohol‐related disorders16,7771
Substance‐related disorders13,6971
Psychiatric disorders41,1534
Mood disorders28,7613
Schizophrenia and other psychotic disorders12,3921
Procedures  
Cardiovascular procedures59,9015
GI procedures31,2243
Mechanical ventilation78531
Hospital characteristics, N=286  
Number of beds  
<20010336
2013006322
3015008128
>5003914
Population served  
Urban22579
Rural6121
Teaching status  
Nonteaching20772
Teaching7928
US Census region  
Northeast4716
Midwest6322
South11540
West6121

To assess hospital variation in opioid prescribing after adjusting for patient characteristics, we used a GEE model of opioid receipt, controlling for all patient characteristics listed in Table 1. We then took the mean of the predicted probabilities of opioid receipt for the patients within each hospital in our cohort to derive the hospital prescribing rate adjusted for patient characteristics. We report the mean, SD, and range of the prescribing rates for the hospitals in our cohort before and after adjustment for patient characteristics.

To assess whether patients admitted to hospitals with higher rates of opioid prescribing have higher relative risk of severe opioid‐related adverse events, we stratified hospitals into opioid‐prescribing rate quartiles and compared the rates of opioid‐related adverse eventsboth overall and among opioid exposedbetween quartiles. To adjust for patient characteristics, we used a GEE model in which severe opioid‐related adverse event (yes/no) was the dependent variable and hospital‐prescribing rate quartile and all patient characteristics in Table 1 were independent variables. We also performed a sensitivity analysis in which we assessed the association between hospital prescribing‐rate quartile and the individual components of our composite outcome. Our results were qualitatively unchanged using this approach, and only the results of our main analysis are presented.

All analyses were carried out using SAS software, version 9.2 (SAS Institute Inc., Cary, NC).

RESULTS

Patient Admission Characteristics

There were 3,190,934 adult admissions to 300 acute‐care hospitals during our study period. After excluding admissions with a length of stay >365 days (n=25), missing patient sex (n=17), and charges for operating‐room procedures or a surgical attending of record (n=2,018,553), 1,172,339 admissions were available for analysis. There were 12 hospitals with incomplete opioid‐prescribing data (n=32,794) and 2 hospitals that contributed <100 admissions each (n=126), leaving 1,139,419 admissions in 286 hospitals in our analytic cohort. The median age of the cohort was 64 years (interquartile range, 4979 years), and 527,062 (46%) were men. Table 1 shows the characteristics of the admissions in the cohort.

Rate, Route, and Dose of Opioid Exposures

Overall, there were 576,373 (51%) admissions with charges for opioid medications. Among those exposed, 244,760 (43%) had charges for multiple opioids during the admission; 172,090 (30%) had charges for 2 different opioids; and 72,670 (13%) had charges for 3 different opioids. Table 2 shows the percent exposed to each opioid, the percent of exposed with parenteral and oral routes of administration, and the mean daily dose received in oral morphine equivalents.

Rate of Exposure, Route of Administration, and Average Dose of Opioids Received, Overall and by Opioid (N=1,139,419)
 ExposedParenteral AdministrationOral AdministrationDose Received, in Oral Morphine Equivalents
 N%aN%bN%bMeanSDc
  • NOTE: Abbreviations: SD, standard deviation.

  • Percentages exposed to different opioids add up to more than total receiving any opioid since patients may be exposed to >1 opioid during their hospitalization.

  • Denominator is the number exposed. Percentages may add up to100% owing to missing route information or receipt of both parenteral and oral routes, respectively.

  • On days on which opioids were received. Charges for tramadol, other category opioids, oral fentanyl (0.7% of fentanyl charges), and epidural‐route opioids (3.5% of fentanyl charges, 0.1% of morphine charges, and 0.1% of hydromorphone charges) were not included in dosage calculations due to lack of standard conversion factor to morphine equivalents. Charges with missing dose were also excluded (2% of total remaining opioid charges). Includes the following opioids: buprenorphine, levorphanol, oxymorphone, pentazocine, propoxyphene, tapentadol, butorphanol, dezocine, and nalbuphine.

All opioids576,37351378,77166371,7966568185
Morphine224,81120209,0409321,6451040121
Hydrocodone162,5581400160,941991412
Hydromorphone146,23613137,9369416,05211113274
Oxycodone126,7331100125,033992637
Fentanyl105,0529103,1139864116475
Tramadol35,57030035,570100  
Meperidine24,850224,3989851523634
Methadone15,3021370214,78197337384
Codeine22,8182178122,18397915
Other45,469458211339,61887  

Among the medications/routes for which conversion to morphine equivalents was possible, dosage was missing in 39,728 out of 2,294,673 opioid charges (2%). The average daily dose received in oral morphine equivalents was 68 mg. A total dose of 50 mg per day was received in 39% of exposed, and a total dose of 100 mg per day was received in 23% of exposed. Among those exposed, 52% (26% of overall admissions) had charges for opioids on the day of discharge.

Rates of Opioid Use by Patient and Hospital Characteristics

Table 3 reports the association between admission characteristics and opioid use. Use was highest in patients between the ages of 25 and 54 years. Although use declined with age, 44% of admissions age 65 years had charges for opioid medication. After adjustment for patient demographics, comorbidities, and hospital characteristics, opioid use was more common in females than males, those age 2554 years compared with those older and younger, those of Caucasian race compared with non‐Caucasian race, and those with Medicare or Medicaid primary insurance. Among the primary discharge diagnoses, patients with musculoskeletal injuries, various specific and nonspecific pain‐related diagnoses, and cancer were significantly more likely to receive opioids than patients without these diagnoses, whereas patients with alcohol‐related disorders and psychiatric disorders were significantly less likely to receive opioids than patients without these diagnoses. Patients admitted to hospitals in the Midwest, South, and West were significantly more likely to receive opioid medications than patients in the Northeast.

Association Between Admission Characteristics and Opioid Use (N=1,139,419)
 Exposed, N=576,373Unexposed, N=563,046% ExposedAdjusted RRa95% CI
  • NOTE: Abbreviations: AIDS, acquired immune deficiency syndrome; CHF, congestive heart failure; CI, confidence interval; DM, diabetes mellitus; GEE, generalized estimating equation; GI, gastrointestinal; ICU, intensive care unit; PVD, peripheral vascular disease; RA, rheumatoid arthritis; ref, reference; RR, relative risk; US, United States.

  • Multivariable GEE model used to account for multiple admissions of the same patient, with simultaneous control for all variables listed in this table.

  • For comorbidities, primary discharge diagnoses, and procedures, the reference group is absence of that condition or procedure.

  • Pain‐related diagnoses include abdominal pain, headache, nonspecific chest pain, pancreatic disorders, musculoskeletal back problems, and calculus of urinary tract.

Patient characteristics     
Age group, y     
182417,36020,10446(ref) 
253437,79328,748571.171.16‐1.19
354460,71241,989591.161.15‐1.17
4554103,79871,032591.111.09‐1.12
5564108,25684,314561.000.98‐1.01
657498,11098,297500.840.83‐0.85
75+150,344218,562410.710.70‐0.72
Sex     
Male255,315271,74748(ref) 
Female321,058291,299521.111.10‐1.11
Race     
White365,107346,88651(ref) 
Black92,01384,980520.930.92‐0.93
Hispanic27,59226,814510.940.93‐0.94
Other91,661104,366470.930.92‐0.93
Marital status     
Married222,912204,73652(ref) 
Single297,742288,601511.000.99‐1.01
Unknown/other55,71969,709440.940.93‐0.95
Primary insurance     
Private/commercial143,954125,77153(ref) 
Medicare traditional236,114266,187471.101.09‐1.10
Medicare managed care59,10467,240471.111.11‐1.12
Medicaid73,58351,442591.131.12‐1.13
Self‐pay/other63,61852,406551.031.02‐1.04
ICU care     
No510,654512,37350(ref) 
Yes65,71950,673561.021.01‐1.03
Comorbiditiesb     
AIDS36552069641.091.07‐1.12
Alcohol abuse35,11244,521440.920.91‐0.93
Deficiency anemias115,84297,595541.081.08‐1.09
RA/collagen vascular disease22,51912,691641.221.21‐1.23
Chronic blood‐loss anemia64444416591.041.02‐1.05
CHF88,895101,190470.990.98‐0.99
Chronic pulmonary disease153,667132,287541.081.08‐1.08
Coagulopathy25,80222,711531.031.02‐1.04
Depression83,05162,502571.081.08‐1.09
DM without chronic complications136,184133,903500.990.99‐0.99
DM with chronic complications38,69632,036551.041.03‐1.05
Drug abuse37,20229,684561.141.13‐1.15
Hypertension344,718351,581500.980.97‐0.98
Hypothyroidism70,78675,350480.990.99‐0.99
Liver disease24,06714,063631.151.14‐1.16
Lymphoma77276305551.161.14‐1.17
Fluid and electrolyte disorders168,814157,762521.041.03‐1.04
Metastatic cancer23,9209515721.401.39‐1.42
Other neurological disorders51,09173,104410.870.86‐0.87
Obesity69,58449,331591.051.04‐1.05
Paralysis17,49721,087450.970.96‐0.98
PVD42,17635,158551.111.11‐1.12
Psychoses38,63863,218380.910.90‐0.92
Pulmonary circulation disease26,65625,450511.051.04‐1.06
Renal failure86,56588,833491.011.01‐1.02
Solid tumor without metastasis16,25813,336551.141.13‐1.15
Peptic ulcer disease excluding bleeding376160701.121.07‐1.18
Valvular disease38,39648,220440.930.92‐0.94
Weight loss25,72419,408571.091.08‐1.10
Primary discharge diagnosesb     
Cancer13,9865182731.201.19‐1.21
Musculoskeletal injuries14,6382160872.022.002.04
Pain‐related diagnosesc64,65636,877641.201.20‐1.21
Alcohol‐related disorders342513,352200.460.44‐0.47
Substance‐related disorders86805017631.031.01‐1.04
Psychiatric disorders725333,900180.370.36‐0.38
Mood disorders594322,81821  
Schizophrenia and other psychotic disorders131011,08211  
Proceduresb     
Cardiovascular procedures50,9978904851.801.79‐1.81
GI procedures27,2064018871.701.69‐1.71
Mechanical ventilation53412512681.371.34‐1.39
Hospital characteristics     
Number of beds     
<200100,90088,43953(ref) 
201300104,21399,995510.950.95‐0.96
301500215,340209,104510.940.94‐0.95
>500155,920165,508490.960.95‐0.96
Population served     
Urban511,727506,80350(ref) 
Rural64,64656,243530.980.97‐0.99
Teaching status     
Nonteaching366,623343,58152(ref) 
Teaching209,750219,465491.000.99‐1.01
US Census region     
Northeast99,377149,44640(ref) 
Midwest123,194120,322511.26(1.25‐1.27)
South251,624213,029541.33(1.33‐1.34)
West102,17880,249561.37(1.36‐1.38)

Variation in Opioid Prescribing

Figure 1 shows the histograms of hospital opioid prescribing rate for the 286 hospitals in our cohort (A) before and (B) after adjustment for patient characteristics. The observed rates ranged from 5% in the lowest‐prescribing hospital to 72% in the highest‐prescribing hospital, with a mean (SD) of 51% (10%). After adjusting for patient characteristics, the adjusted opioid‐prescribing rates ranged from 33% to 64%, with a mean (SD) of 50% (4%).

Figure 1
Histograms of hospital opioid prescribing rate (A) before and (B) after adjustment for patient characteristics.

Severe Opioid‐Related Adverse Events

Among admissions with opioid exposure (n=576,373), naloxone use occurred in 2345 (0.41%) and opioid‐related adverse drug events in 1174 (0.20%), for a total of 3441 (0.60%) severe opioid‐related adverse events (some patients experienced both). Table 4 reports the opioid exposure and severe opioid‐related adverse‐event rates within hospital opioid‐prescribing rate quartiles, along with the adjusted association between the hospital opioid‐prescribing rate quartile and severe opioid‐related adverse events. After adjusting for patient characteristics, the relative risk of a severe opioid‐related adverse event was significantly greater in hospitals with higher opioid‐prescribing rates, both overall and among opioid exposed.

Association Between Hospital Opioid‐Prescribing Rate Quartile and Risk of an Opioid‐Related Adverse Event
QuartileNo. of PatientsOpioid Exposed, n (%)Opioid‐Related Adverse Events, n (%)Adjusted RR in All Patients, RR (95% CI), N=1,139,419aAdjusted RR in Opioid Exposed, RR (95% CI), N=576,373a
  • NOTE: Abbreviations: CI, confidence interval; GEE, generalized estimating equation; ref, reference; ref, reference; RR, relative risk.

  • Adjusted for repeated admissions and patient characteristics presented in Table 1 using a multivariable GEE model with a Poisson error term distribution, log link, and autoregressive correlation structure.

1349,747132,824 (38)719 (0.21)(ref)(ref)
2266,652134,590 (50)729 (0.27)1.31 (1.17‐1.45)1.07 (0.96‐1.18)
3251,042139,770 (56)922 (0.37)1.72 (1.56‐1.90)1.31 (1.19‐1.44)
4271,978169,189 (62)1071 (0.39)1.73 (1.57‐1.90)1.23 (1.12‐1.35)

DISCUSSION

In this analysis of a large cohort of hospitalized nonsurgical patients, we found that more than half of all patients received opioids, with 43% of those exposed receiving multiple opioids during their admission and 52% receiving opioids on the day of discharge. Considerable hospital variation in opioid use was evident, and this was not fully explained by patient characteristics. Severe opioid‐related adverse events occurred more frequently at hospitals with higher opioid‐prescribing rates, and the relative risk of a severe adverse event per patient prescribed opioids was also higher in these hospitals. To our knowledge, this is the first study to describe the scope of opioid utilization and the relationship between utilization and severe opioid‐related adverse events in a sample of nonsurgical patients in US acute‐care facilities.

Our use of naloxone charges and opioid‐specific ICD‐9‐CM coding to define an opioid‐related adverse event was intended to capture only the most severe opioid‐related adverse events. We chose to focus on these events in our analysis to maximize the specificity of our outcome definition and thereby minimize confounding in our observed associations. The rate of less‐severe opioid‐related adverse events, such as nausea, constipation, and pruritis, is likely much higher and not captured in our outcome definition. Prior analyses have found variable rates of opioid‐related adverse events of approximately 1.8% to 13.6% of exposed patients.[22, 23, 24] However, these analyses focused on surgical patients and included less‐severe events. To our knowledge, ours is the first analysis of severe opioid‐related adverse events in nonsurgical patients.

Our finding that severe opioid‐related adverse events increase as opioid prescribing increases is consistent with that which has been demonstrated in the community setting, where rates of opioid‐related adverse events and mortality are higher in communities with higher levels of opioid prescribing.[2, 8, 25] This finding is expected, as greater use of a class of medications with known side effects would be expected to result in a higher overall rate of adverse events. More concerning, however, is the fact that this relationship persists when focusing exclusively on opioid‐exposed patients. Among similar patients receiving opioids at different hospitals, those hospitalized in facilities with higher opioid‐prescribing rates have higher rates of severe opioid‐related adverse events. This suggests that hospitals that use opioids more frequently do not do so more safely. Rather, the increased overall prescribing rates are associated with heightened risk for a serious adverse event per patient exposed and may reflect unsafe prescribing practices.

Furthermore, our results demonstrate both regional and hospital variation in use of opioids not fully explained by patient characteristics, similar to that which has been demonstrated for other drugs and heathcare services.[26, 27, 28, 29, 30] The implications of these findings are limited by our lack of information on pain severity or prior outpatient treatment, and our resultant inability to evaluate the appropriateness of opioid use in this analysis. Additionally, although we controlled for a large number of patient and hospital characteristics, there could be other significant predictors of use not accounted for in our analysis. However, it seems unlikely that differential pain severity or patient characteristics between patients in different regions of the country could fully explain a 37% relative difference in prescribing between the lowest‐ and highest‐prescribing regions, after accounting for the 44 patient‐level variables in our models. Whereas variation in use unrelated to patient factors could represent inappropriate prescribing practices, it could also be a marker of uncertainty regarding what constitutes appropriate prescribing and high‐quality care in this realm. Although guidelines advocate for standard pain assessments and a step‐up approach to treatment,[31, 32, 33] the lack of objective measures of pain severity and lack of evidence‐based recommendations on the use of opioids for noncancer pain[34] will almost certainly lead to persistent variation in opioid prescribing despite guideline‐driven care.

Nonetheless, our findings suggest that opportunities exist to make opioid prescribing safer in hospitalized patients. Studies aimed at elucidating the source of regional and hospital variation are necessary. Additionally, efforts should focus on identifying patient and prescribing characteristics associated with heightened risk of opioid‐related adverse events. Prior studies have demonstrated that the risks of opioid medications increase with increasing age of the patient.[35, 36] Although opioid use in our cohort declined with age, 44% of admissions age 65 years had charges for opioid medications. Studies in outpatients have also demonstrated that the risks of opioid overdose and overdose‐related death increase with dose.[5, 7] One study demonstrated a 3.7‐fold increased risk of overdose at doses of 5099 mg/day in oral morphine equivalents, and an 8.9‐fold increased risk at doses of 100 mg/day, compared with doses of 20 mg/day.[7] The prevalence of high dose exposure observed in our cohort, coupled with the older age of hospitalized patients, suggests potential targets for promoting safer use in hospitalized patients through interventions such as computerized decision support and enhanced monitoring in those at highest risk.

Because medications after discharge were unavailable in our dataset, the percentage of patients given a prescription for opioid medication on discharge is unknown. However, given that opioids are often tapered rather than abruptly discontinued, our finding that 26% of hospitalized nonsurgical patients received opioids on the day of discharge suggests that a substantial proportion of patients may be discharged with a prescription for opioid medication. Given the possibility of coexistent outpatient opioid prescriptions, these findings draw attention to the importance of assuring development and streamlined accessibility of data from state prescription drug monitoring programs and suggest that increased attention should be paid to the role that inpatient opioid prescribing plays in the increased rates of chronic opioid use and overdose‐related deaths in the United States.

There are additional limitations to our analysis. First, although the database used for this analysis captures a large proportion of admissions to US acute‐care facilities and is similar in composition, it is possible that participating medical centers differ from nonparticipating medical centers in ways that could be associated with opioid prescribing. Additionally, although Premier performs extensive validation and correction processes to assure the quality of their data, there is still likely to be a small amount of random error in the database, which could particularly impact dosage calculations. The lack of preadmission medications in our database precluded identification of the proportion of patients newly started on opioid medications. Lastly, it is possible that the hospital prescribing‐rate quartile is associated with patient characteristics unaccounted for in our analysis, and, therefore, the possibility of residual confounding still exists.

In conclusion, the majority of hospitalized nonsurgical patients are exposed to opioid medications during the course of their hospitalizations, often at high doses. More than half of those exposed are still receiving these medications on the day of discharge. We found hospital and regional variation in opioid use that was not fully explained by patient characteristics, and higher levels of hospital use were associated with higher risk of severe opioid‐related adverse events in opioid‐exposed patients. Further research is necessary to investigate the appropriateness of opioid use in this patient population, the sources of variation in use, and the predictors of opioid‐related adverse events in hospitalized patients to allow development of interventions to make hospital use safer.

Disclosures

Disclosures: Dr. Herzig had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Dr. Herzig was funded by grant no. K23AG042459 from the National Institute on Aging. Dr. Marcantonio was funded by grant nos. P01AG031720, R01AG030618, R03AG028189, and K24AG035075 from the National Institute on Aging. The funding organization had no involvement in any aspect of the study, including design, conduct, and reporting of the study. None of the authors have any conflicts of interest to disclose.

References
  1. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med. 2010;363(21):19811985.
  2. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf. 2006;15(9):618627.
  3. Pletcher MJ, Kertesz SG, Kohn MA, Gonzales R. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA. 2008;299(1):7078.
  4. Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA. 2000;283(13):17101714.
  5. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose‐related deaths. JAMA. 2011;305(13):13151321.
  6. Cerdá M, Ransome Y, Keyes KM, et al. Prescription opioid mortality trends in New York City, 1990–2006: examining the emergence of an epidemic. Drug Alcohol Depend. 2013;132(1‐2):5362.
  7. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):8592.
  8. Modarai F, Mack K, Hicks P, et al. Relationship of opioid prescription sales and overdoses, North Carolina. Drug Alcohol Depend. 2013;132(1‐2):8186.
  9. Tanne JH. Deaths from prescription opioids soar in New York. BMJ. 2013;346:f921.
  10. Haupt M, Cruz‐Jentoft A, Jeste D. Mortality in elderly dementia patients treated with risperidone. J Clin Psychopharmacol. 2006;26(6):566570.
  11. Pronovost P, Weast B, Schwarz M, et al. Medication reconciliation: a practical tool to reduce the risk of medication errors. J Crit Care. 2003;18(4):201205.
  12. Rozich JD, Haraden CR, Resar RK. Adverse drug event trigger tool: a practical methodology for measuring medication related harm. Qual Saf Health Care. 2003;12(3):194200.
  13. Nwulu U, Nirantharakumar K, Odesanya R, McDowell SE, Coleman JJ. Improvement in the detection of adverse drug events by the use of electronic health and prescription records: an evaluation of two trigger tools. Eur J Clin Pharmacol. 2013;69(2):255259.
  14. Elixhauser A, Owens P. Adverse Drug Events in U.S. Hospitals, 2004. Rockville, MD: Agency for Healthcare Research and Quality; April 2007. Statistical Brief 29.
  15. Lucado J, Paez K, Elixhauser A. Medication‐Related Adverse Outcomes in U.S. Hospitals and Emergency Departments, 2008. Rockville, MD: Agency for Healthcare Research and Quality; April 2011. Statistical Brief 109.
  16. US Centers for Medicare and Medicaid Services. Hospital‐Acquired Conditions (Present on Admission Indicator). Available at: http://www.cms.hhs.gov/HospitalAcqCond/. Accessed August 16, 2011. Updated September 20, 2012.
  17. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of morphine and opiates. J Intern Med. 2006;260(1):7687.
  18. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):827.
  19. Clinical Classifications Software, Healthcare Cost and Utilization Project (HCUP). Rockville, MD; Agency for Healthcare Research and Quality; December 2009.
  20. Gammaitoni AR, Fine P, Alvarez N, McPherson ML, Bergmark S. Clinical application of opioid equianalgesic data. Clin J Pain. 2003;19(5)286297.
  21. Svendsen K, Borchgrevink PC, Fredheim O, Hamunen K, Mellbye A, Dale O. Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses. Palliat Med. 2011;25(7):725732.
  22. Kessler ER, Shah M, Gruschkus SK, Raju A. Cost and quality implications of opioid‐based postsurgical pain control using administrative claims data from a large health system: opioid‐related adverse events and their impact on clinical and economic outcomes. Pharmacotherapy. 2013;33(4):383391.
  23. Oderda GM, Said Q, Evans RS, et al. Opioid‐related adverse drug events in surgical hospitalizations: impact on costs and length of stay. Ann Pharmacother. 2007;41(3):400406.
  24. Oderda GM, Evans RS, Lloyd J, et al. Cost of opioid‐related adverse drug events in surgical patients. J Pain Symptom Manage. 2003;25(3):276283.
  25. Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med. 2006;31(6):506511.
  26. O'Connor GT, Quinton HB, Traven ND, et al. Geographic variation in the treatment of acute myocardial infarction: the Cooperative Cardiovascular Project. JAMA. 1999;281(7):627633.
  27. Pilote L, Califf RM, Sapp S, et al; GUSTO‐1 Investigators. Regional variation across the United States in the management of acute myocardial infarction. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med. 1995;333(9):565572.
  28. Steinman MA, Landefeld CS, Gonzales R. Predictors of broad‐spectrum antibiotic prescribing for acute respiratory tract infections in adult primary care. JAMA. 2003;289(6):719725.
  29. Zhang Y, Baicker K, Newhouse JP. Geographic variation in Medicare drug spending. N Engl J Med. 2010;363(5):405409.
  30. Zhang Y, Steinman MA, Kaplan CM. Geographic variation in outpatient antibiotic prescribing among older adults. Arch Intern Med. 2012;172(19):14651471.
  31. Cantrill SV, Brown MD, Carlisle RJ, et al. Clinical policy: critical issues in the prescribing of opioids for adult patients in the emergency department. Ann Emerg Med. 2012;60(4):499525.
  32. The Joint Commission. Facts About Pain Management. Available at: http://www.jointcommission.org/pain_management/. Accessed July 23, 2012.
  33. The Joint Commission. Sentinel Event Alert: Safe Use of Opioids in Hospitals. Published August 8, 2012. Available at: http://www.jointcommission.org/assets/1/18/SEA_49_opioids_8_2_12_final.pdf. Accessed March 4, 2013.
  34. Chou R, Ballantyne JC, Fanciullo GJ, Fine PG, Miaskowski C. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10(2):147159.
  35. Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short‐term administration: effect of age, gender, and race. Clin Pharmacol Ther. 2003;74(2):102112.
  36. Taylor S, Kirton OC, Staff I, Kozol RA. Postoperative day one: a high‐risk period for respiratory events. Am J Surg. 2005;190(5):752756.
References
  1. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med. 2010;363(21):19811985.
  2. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf. 2006;15(9):618627.
  3. Pletcher MJ, Kertesz SG, Kohn MA, Gonzales R. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA. 2008;299(1):7078.
  4. Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA. 2000;283(13):17101714.
  5. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose‐related deaths. JAMA. 2011;305(13):13151321.
  6. Cerdá M, Ransome Y, Keyes KM, et al. Prescription opioid mortality trends in New York City, 1990–2006: examining the emergence of an epidemic. Drug Alcohol Depend. 2013;132(1‐2):5362.
  7. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):8592.
  8. Modarai F, Mack K, Hicks P, et al. Relationship of opioid prescription sales and overdoses, North Carolina. Drug Alcohol Depend. 2013;132(1‐2):8186.
  9. Tanne JH. Deaths from prescription opioids soar in New York. BMJ. 2013;346:f921.
  10. Haupt M, Cruz‐Jentoft A, Jeste D. Mortality in elderly dementia patients treated with risperidone. J Clin Psychopharmacol. 2006;26(6):566570.
  11. Pronovost P, Weast B, Schwarz M, et al. Medication reconciliation: a practical tool to reduce the risk of medication errors. J Crit Care. 2003;18(4):201205.
  12. Rozich JD, Haraden CR, Resar RK. Adverse drug event trigger tool: a practical methodology for measuring medication related harm. Qual Saf Health Care. 2003;12(3):194200.
  13. Nwulu U, Nirantharakumar K, Odesanya R, McDowell SE, Coleman JJ. Improvement in the detection of adverse drug events by the use of electronic health and prescription records: an evaluation of two trigger tools. Eur J Clin Pharmacol. 2013;69(2):255259.
  14. Elixhauser A, Owens P. Adverse Drug Events in U.S. Hospitals, 2004. Rockville, MD: Agency for Healthcare Research and Quality; April 2007. Statistical Brief 29.
  15. Lucado J, Paez K, Elixhauser A. Medication‐Related Adverse Outcomes in U.S. Hospitals and Emergency Departments, 2008. Rockville, MD: Agency for Healthcare Research and Quality; April 2011. Statistical Brief 109.
  16. US Centers for Medicare and Medicaid Services. Hospital‐Acquired Conditions (Present on Admission Indicator). Available at: http://www.cms.hhs.gov/HospitalAcqCond/. Accessed August 16, 2011. Updated September 20, 2012.
  17. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of morphine and opiates. J Intern Med. 2006;260(1):7687.
  18. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):827.
  19. Clinical Classifications Software, Healthcare Cost and Utilization Project (HCUP). Rockville, MD; Agency for Healthcare Research and Quality; December 2009.
  20. Gammaitoni AR, Fine P, Alvarez N, McPherson ML, Bergmark S. Clinical application of opioid equianalgesic data. Clin J Pain. 2003;19(5)286297.
  21. Svendsen K, Borchgrevink PC, Fredheim O, Hamunen K, Mellbye A, Dale O. Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses. Palliat Med. 2011;25(7):725732.
  22. Kessler ER, Shah M, Gruschkus SK, Raju A. Cost and quality implications of opioid‐based postsurgical pain control using administrative claims data from a large health system: opioid‐related adverse events and their impact on clinical and economic outcomes. Pharmacotherapy. 2013;33(4):383391.
  23. Oderda GM, Said Q, Evans RS, et al. Opioid‐related adverse drug events in surgical hospitalizations: impact on costs and length of stay. Ann Pharmacother. 2007;41(3):400406.
  24. Oderda GM, Evans RS, Lloyd J, et al. Cost of opioid‐related adverse drug events in surgical patients. J Pain Symptom Manage. 2003;25(3):276283.
  25. Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med. 2006;31(6):506511.
  26. O'Connor GT, Quinton HB, Traven ND, et al. Geographic variation in the treatment of acute myocardial infarction: the Cooperative Cardiovascular Project. JAMA. 1999;281(7):627633.
  27. Pilote L, Califf RM, Sapp S, et al; GUSTO‐1 Investigators. Regional variation across the United States in the management of acute myocardial infarction. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med. 1995;333(9):565572.
  28. Steinman MA, Landefeld CS, Gonzales R. Predictors of broad‐spectrum antibiotic prescribing for acute respiratory tract infections in adult primary care. JAMA. 2003;289(6):719725.
  29. Zhang Y, Baicker K, Newhouse JP. Geographic variation in Medicare drug spending. N Engl J Med. 2010;363(5):405409.
  30. Zhang Y, Steinman MA, Kaplan CM. Geographic variation in outpatient antibiotic prescribing among older adults. Arch Intern Med. 2012;172(19):14651471.
  31. Cantrill SV, Brown MD, Carlisle RJ, et al. Clinical policy: critical issues in the prescribing of opioids for adult patients in the emergency department. Ann Emerg Med. 2012;60(4):499525.
  32. The Joint Commission. Facts About Pain Management. Available at: http://www.jointcommission.org/pain_management/. Accessed July 23, 2012.
  33. The Joint Commission. Sentinel Event Alert: Safe Use of Opioids in Hospitals. Published August 8, 2012. Available at: http://www.jointcommission.org/assets/1/18/SEA_49_opioids_8_2_12_final.pdf. Accessed March 4, 2013.
  34. Chou R, Ballantyne JC, Fanciullo GJ, Fine PG, Miaskowski C. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10(2):147159.
  35. Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short‐term administration: effect of age, gender, and race. Clin Pharmacol Ther. 2003;74(2):102112.
  36. Taylor S, Kirton OC, Staff I, Kozol RA. Postoperative day one: a high‐risk period for respiratory events. Am J Surg. 2005;190(5):752756.
Issue
Journal of Hospital Medicine - 9(2)
Issue
Journal of Hospital Medicine - 9(2)
Page Number
73-81
Page Number
73-81
Publications
Publications
Article Type
Display Headline
Opioid utilization and opioid‐related adverse events in nonsurgical patients in US hospitals
Display Headline
Opioid utilization and opioid‐related adverse events in nonsurgical patients in US hospitals
Sections
Article Source

© 2013 Society of Hospital Medicine

Disallow All Ads
Correspondence Location
Address for correspondence and reprint requests: Shoshana J. Herzig, MD, Beth Israel Deaconess Medical Center, 1309 Beacon St, Brookline, MA 02446; Telephone: 617‐754‐1413; Fax: 617‐754‐1440; E‐mail: sherzig@bidmc.harvard.edu
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Article PDF Media
Media Files